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STRUCTURAL STUDIES OF TALIN-MEDIATED INTEGRIN ACTIVATION

ESEN BAKHAUTDIN

ABSTRACT
Activation of heterodimeric (/) integrin transmembrane receptors by the cytoskeletal
protein talin is essential for many important cell adhesive responses including cellextracellular matrix contact, cell motility and survival. A key step in this process involves
interaction of phosphotyrosine-binding (PTB) domain in the N-terminal head of talin
(talin-H) with integrin 3membrane-proximal cytoplasmic tails (-MP-CTs). Compared
to talin-H, intact talin exhibits low potency in inducing integrin activation. Using TROSY
NMR spectroscopy, we found that the large C-terminal rod domain of talin (talin-R)
interacts with talin-H and allosterically restrains talin in a closed conformation.
Structural, mutational, and biochemical analyses demonstrate that talin-R specifically
masks a region in talin-PTB where integrin 3-MP-CT binds and competes with it for
binding to talin-PTB. The inhibitory interaction is disrupted by a constitutively activating
mutation (M319A) or phosphatidylinositol 4,5-bisphosphate – a known talin activator.
These data define a distinct autoinhibition mechanism for talin and suggest how it
controls the dynamics of integrin activation and cell adhesion.
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CHAPTER I
INTRODUCTION
PART A. INTEGRIN ACTIVATION
Integrins
Integrins, heterodimeric cell surface receptors, are vital adhesion molecules that
mediate cell-extracellular matrix (ECM) and cell-cell interactions for the homeostasis of
animal species from drosophila to human (Hynes, 2002). They have critical roles in cell
adhesion and migration which are crucial for embryonic development, hemostasis and
angiogenesis. For example; in the presence of injury, the body’s primary action is to stop
the bleeding by mediating platelet adhesion and aggregation through activating the
fibrinogen receptors on platelets, integrin IIb3. Also, during development migrating
cells require activated integrins to be localized at the leading edge of the cell for the
formation of proper cell adhesion. Similarly, during inflammation leukocytes adhere to
and migrate across the endothelium through integrin activation (Moser et al., 2009).

Integrin family has more than 20 members and all of their structure and ligand
binding mechanism exhibit similarity. Integrins are formed by non-covalent  and 
heterodimers. The 1 chains, which form dimers with at least 9 distinct  chains, are
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found to be on almost all vertebrte cells. 51, for example is a fibronectin receptor, and
61 is a laminin recptor on many type of cells. In contrast, 2 chains form dimers with
4 types of  chains, and expressed on the surface of white blood cells. Their role is
mainly to mediate cell-cell, rather than cell-matrix interactions. The 2 integrins enable
white blood cells to attach firmly and cross the endothelium to reach at the sites of
infection. Humans with leukocyte adhesion deficiency syndrome are unable to synthesize
2 receptors in their white blood cells; as a consequence, they suffer from repeated
bacterial infections leading to early death (Hynes, 2002). 3 integrins are found on a
variety of cells, including platelets which interact with fibrinogen during blood clotting,
and humans with Glanzman’s disease, who are genetically deficient in 3 integrins,
suffer from severe bleeding (Hodivala-Dilke et al., 1999).

Integrin Structure
Integrins  and  subunits have a large (more than 700 residue) N-terminal extracellular
domain, a short (approximately 20 residues) transmembrane domain, and a short (13-70
residues) cytoplasmic tail (Figure1.1.). The crystal structures of the extracellular domain
of v3, without and with a bound RGD peptide have provided valuable information
about integrin structure (Xiong et al., 2001; 2002). The extracellular domain of the 
subunit has a seven-bladed -propeller domain, a thigh domain, and calf-1 and calf-2
domains. Some of  integrins have an I domain which contains a conserved metal iondependent adhesion site (MIDAS) to bind divalent cations including Ca2+, Mg2+, and
Mn2+ for proper integrin-ligand interaction. The  subunit is composed of an A domain,

2

Figure 1.1. Structural organization and activation of integrins. The crystal structure of
the extracellular domain, a molecular model of the transmembrane region and NMR
structures of the cytoplasmic tails have been adjoined to create a depiction of IIb3.
The equilibrium between a bent and an extended form of integrins are illustrated. The
figure and legend is adapted from Ma et al, 2007.

3

which is the analog of the I domain of the  integrin subunit, hybrid domain, PSI
(plexin/semaphoring/integrin) domain, 3 EGF (epidermal growth factor) domains and a
membrane-proximal  tail domain (TD). The extracellular domain of / heterodimer
has a ligand binding domain and two legs. The ligand binding domain has a head-like
structure and it is formed by the interaction between seven-bladed -propeller of the 
subunit and the A domain of the  subunit. The integrin v3-ligand RGD peptideMn2+ ion complex structure reveals that ligand binds to an interface between  subunits,
and has contact with a metal-occupied MIDAS in the integrin head. Both structural and
biochemical analyses have provided snapshots of different conformational changes of
integrins that occur during the transition from inactive to active state. In the resting state,
integrins are in inactive state where they have a bent conformation. Agonist stimulation
initiates structural changes across the whole integrin which leads to the conversion of the
bent form of the integrins to an extended form with a higher-affinity ligand binding.

The structure of the short transmembrane (TM) domains is well-defined after two
recent publications of the complex structure of the integrin IIb3 TM domain (Lau et
al., 2009; Yang et al., 2009). The IIb TM domain is a 24-aa straight helix which
occupies the whole plasma membrane, whereas the 3 TM domain, a 30-aa a helix, is
supposed to be tilted within the plasma membrane due to its longer helix length compared
to membrane width. Both NMR structures of the integrin IIb3 TM domain (Lau et al.,
2009; Yang et al., 2009) are in agreement on TM assembly but differ in CT portion. On
the basis of the heterodimeric IIb3 TM structures, in the resting state, associated TM
helices are stabilized by dimer interface. Either extracellular or intracellular signaling
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destabilizes TM dimer interface, shifting the equilibrium to the dissociated state and
allowing the extracellular domains to rearrange its conformation for high-affinity ligand
binding.

In the integrin family, short  and  cytoplasmic tails show a high sequence
homology, especially in the membrane proximal region. Nuclear magnetic resonance
(NMR) studies revealed that a complex forms between IIb and 3 CT membrane
proximal helices (Vinogradova et al., 2002). This interaction is stabilized by hydrophobic
and electrostatic interactions and a salt bridge between IIbR995 residue and 3D723
residue. The mutational analyses confirm the existence of the clasp between two integrin
subunit regions, which stabilizes the inactive integrins in the resting state. However, these
interactions were not detected by others, suggesting that the clasp between the MP IIb
and 3 CT helices must be weak (Ulmer et al., 2001). The membrane-distal region of
IIbCT has a divalent ion binding site (Haas et al., 1996) and a turn formed by NRPP
motif (Vinogradova et al., 2000). However, further investigation is needed to understand
the significance of these structural elements. Almost all  tails have highly conserved two
NXXY motifs which serve as recognition sites for proteins containing phosphotyrosine
binding (PTB) domains (Calderwood et al., 2003). Integrin-binding proteins including
talin and kindlins interact specifically with these motifs and regulate integrin activation.

Regulation of outside-in and inside-out integrin signaling
Integrin activation is known to be bidirectional, from outside-in and inside-out
depending on intracellular and extracellular signals. To accomplish their bidirectional

5

functions, integrins are always in equilibrium between resting and activated states, and a
series of coordinated and linked conformational changes take place during the transition
from low-affinity to high-affinity state. Agonist-dependent intracellular signals initiate
the “inside-out signaling” whereas extracellular ligand binding to integrins promotes
“outside-in signaling”.

Inside-out Signaling
During inside-out signaling, integrin activation is tightly regulated by the changes
in interactions and in the structures of the integrins. In the low affinity (inactive) state,
integrins are associated by a ‘clasp’ between  and  subunits, thus preventing integrin
activation. The clasp between membrane- proximal regions of  and  subunits has been
shown to be stabilized by a salt bridge between a conserved arginine residue of  tail and
an aspartate residue of  tail (Vinogradova et al., 2002). The integrin cytoplasmic tails
also play an important role in regulating integrin affinity, especially by binding to
cytoplasmic adaptor protein, talin (Calderwood et al., 1999; 2002; Tadokoro et al., 2003).
Upon agonist stimulation, talin relieves from its autoinhibitory interaction, and only talin
F3-PTB subdomain binds integrin 3 tails and results in integrin activation by a two-step
interaction. In the first step, talin-PTB domain engages the membrane-distal (MD) part of
the 3 integrin tail, which becomes ordered, but the - clasp remains intact. In the
subsequent step, PTB engages the membrane-proximal part of the 3 tail, while
maintaining the MD interaction (Wegener et al., 2007). This interaction destabilizes the
clasp, relieving the salt bridge, and leads to additional electrostatic interactions between
membrane lipids and F3 subdomain. The unclasping of integrin  and  tails leads to
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separation of integrin TM domains, and formation of homomeric dimers and trimers of 
and  transmembrane helices (Li et al, 2001; 2003). Although there is no structural
evidence,

several

biochemical

studies

suggest

that

homo-oligomerization

in

transmembrane domains provide a driving force for integrin activation and clustering (Li
et al, 2004; Li et al, 2005).

Outside-in Signaling
Outside-in signaling is initiated by binding of adhesive ligands such as fibrinogen,
von Willebrand factor (VWF) and fibronectin to integrin extracellular domain. These
interactions lead to further conformational changes that are transmitted through
transmembrane region to the cytoplasmic tails that causes irreversible integrin clustering.
Structural and biochemical studies have revealed that in the resting platelets, Src and its
regulatory kinase , Csk, are bound to IIb3, and upon ligand binding, Csk dissociates
from IIb3, enabling Src and Syk protein tyrosine kinases to become activated
(Obergfell et al., 2002). This results in the phosphorylation of downstream adaptor and
effector molecules for actin polymerization. Thus, outside-in signaling is initiated by the
activation of Src and Syk kinases, and further signaling is generated from IIb3 to actin
cytoskeleton for platelet activation. More biochemical and structural input is required for
a better understanding of the outside-in signaling mechanism.

Talin and its functions
Talin is a high molecular weight cytosolic protein that was initially purified from
human platelets and chicken gizzard (Molony et al., 1987).
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Discovered in high

concentrations at regions of cell-substratum contact (Burridge and Connell, 1983), talin
has long been known to be a physical linker between the integrin and the actin
cytoskeleton, which regulates a variety of cellular processes such as cell spreading, cell
migration, and cell proliferation (Turner and Burridge, 1991; Calderwood et al., 2000).
Recent advances have revealed an additional and especially important role for talin, by
binding to integrin  CTs, talin was found to induce high affinity ligand binding of
integrins, i.e., integrin activation (Tadokoro et al., 2003; Wegener et al., 2007) - a major
step in integrin-mediated cell-ECM adhesion, migration, and numerous physiological and
pathophysiological responses (Hynes, 2002).

Gene expression analysis revealed that there are two talin genes (Tln1 and Tln2) in
vertebrates encoding 74% identical proteins (Monkley et al., 2001; Senetar et al., 2005).
Although Tln2 is larger and have more complex gene than Tln1, most studies have
focused on Tln1. Disruption of Tln1 gene in mice have arrested the gastrulation stage of
the embryonic development due to absence of cell spreading, and focal adhesion (FA)
assembly (Monkley et al., 2000), whereas N-terminal half of Tln2 is sufficient for
embryonic development and mouse survival (Chen et al., 2005). Disruption of both Tln1
alleles in mouse embryonic stem cells have confirmed the previous knock-out studies that
talin1 is required for proper cell spreading and FA assembly (Priddle et al., 1998). A
recent talin1 depletion study revealed that only full-length talin can provide a physical
linkage between the extracellular matrix and the actin cytoskeleton required for FA
assembly and signaling (Zhang et al., 2008).
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Talin Structure
Talin is a high molecular weight protein containing an N-terminal head (1-433,
talin-H, 50 kDa) and a C-terminal rod domain (434-2541, talin-R, 220 kDa) (Figure 1.2.)
in an equilibrium between monomeric and dimeric forms (Rees et al, 1990). Talin-H is
globular, containing a FERM (4.1, ezrin, radixin, moesin) domain composed of three
separate lobes, F1, F2, and F3 and an F0 subdomain with no homology to known
domains. The F3 subdomain resembles a phosphotyrosine-binding (PTB) domain and
binds NPxY motif on integrin  tails (Garcia-Alvarez et al., 2003). The attempts to
crystallize the entire FERM domain was unsuccessful probably due to 30-aminoacid
unstructured loop of

F1 domain. The loop contains two phosphorylation sites

(T144/T150) in platelet talin (Ratnikov et al., 2005), and psychological importance of
these phosphorylations is not known. The linker region (401-481) between head and rod
domains is cleaved in the intact talin by different proteases; the best known is the calpainII (Rees et al., 1990). Although secondary structure predictions show the linker largely
unstructured, numerous phosphorylation sites have been detected (Ratnikov et al., 2005),
and how these phosphorylations affect the intact talin structure and functions needed to
be studied. Talin-Rod is highly elongated, containing a series of helical bundle structures
separated by linkers (McLachlan et al., 1994; Papagrigoriou et al., 2004; Fillingham et
al., 2005; Gingras et al., 2008). Both the N-terminal region of the rod and the C-terminal
half of the rod is made up of a series of five-helix bundles (Papagrigoriou et al., 2004;
Gingras et al., 2008). However, the globular structure of the middle segment between two
ends requires further investigation.
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Figure 1.2. Domain structure of talin. The N-terminal talin head (1-400) contains a
FERM domain comprising F1, F2, and F3 domains preceded by the F0 domain. The talin
rod (482-2541) contains 62 amphipathic a-helices, the most C-terminal of which is
required for talin dimerization (blue). The position of various ligand-binding sites is
indicated, including the intramolecular interaction between F3 and the talin rod. Helices
containing vinculin binding sites (VBS) are numbered-helices 4, 12, and 46 contain
VBS1-3. The figure and legend is adapted from Critchley DR, 2009.
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Binding Partners of Talin
The F3 or PTB domain binds the cytoplasmic tails of -integrins (Calderwood et
al., 2002), phosphotidylinositol 4-phosphate 5-kinase  (PIPK) (Ling et al., 2002; Di
paolo et al., 2002) and the hyaluronan receptor layilin (Wegener et al., 2008), whereas
rod domain has multiple vinculin binding sites (Gingras et al., 2005), a recently identified
a-synemin-binding site (Sun et al., 2008), two actin-binding sites (Hemmings et al., 1996)
and a second integrin binding site (Xing et al., 2001; Tremuth et al., 2004) (Figure 1.2.).
The C-terminus of the rod domain contains I/LWEQ motif that mediates the dimerization
of the talin and facilitates the linkage between talin and F-actin (Gingras et al., 2008;
Smith et al., 2007). The talin-head also contains an F-actin binding site (Lee et al., 2004),
and recent studies have identified Wech proteins which are crucial for the integrincytoskeleton link (Loer et al., 2008). Finally, the talin head binds phospholipids and
inserts into lipid bilayers (Goldman et al., 1992; Heise et al., 1991).

Regulation of talin-mediated integrin activation
Since integrin activation is tightly regulated, talin-integrin interaction has to be
strictly controlled by different cellular mechanisms. Several studies show that there may
be two or more mechanisms, which include autoinhibition of talin, phosphorylation, and
regulatory interactions with different proteins, for the regulation of talin-mediated
integrin activation. Autoinhibition, one of the mechanisms, is a widespread phenomenon
in controlling protein functions, which has been shown to occur in multiple FERMcontaining proteins (Pearson et al., 2000; Li et al., 2007; Lietha et al., 2007). These
studies revealed that in the Ezrin, Radixin, Moesin (ERM) proteins ligand binding sites
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located in the FERM domain are masked by intramolecular interactions. Talin also
belongs to this ERM protein family, and has a FERM domain, creating a possibility that
integrin binding sites could be masked by a similar fashion interaction. Calpain-II has
been shown to cleave talin into a talin-H/talin-R mixture, thereby releasing talin-H for
leading to enhanced binding to integrin (Yan et al., 2001). Talin-H and isolated PTB
domain bind to 3 cytoplasmic tail with six-fold higher affinity than full-length talin
(Calderwood et al., 2002; Yan et al., 2001). These studies support the possibility that
integrin binding site is masked in intact talin, and conformational change is required for
its exposure. What is the mechanism to trigger the conformational change of talin to
expose its integrin binding site? One possible mechanism appears to involve
phosphoinositide binding which lead to the unmasking of the ligand binding site located
in the FERM domain in ERM proteins (Pearson et al., 2000; Hamada et al., 2000).
Indeed, PIP2 has been shown to promote strong talin binding to the integrin  CT
(Martel et al., 2001). Interestingly, the PIP2-producing enzyme, PIPKI, has been shown
to be recruited to the integrin adhesion sites by talin (Ling et al., 2002; di Paolo et al.,
2002) upon its phosphorylation by Src kinase (Ling et al., 2003), providing a mechanism
for efficient PIP2/talin interaction. Thus, upon agonist stimulation, talin may recruit
PIPKI to locally enrich PIP2, which in turn induces the conformational change of talin
to expose its integrin binding site, promoting the high affinity talin binding to and
activation of integrins. The effect of this positive feedback loop can be reversed by the
accumulation of phosphorylated PIPKIwhich competes with integrin  tails for an
overlapping binding site on talin PTB domain (Barsukov et al., 2003; de Pereda et al.,
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2005) and by Src kinase phosphorylation of 3 tail (Datta et al., 2002) which inhibits
talin binding.

Phosphorylation is one of the mechanisms of regulation of talin-mediated integrin
activation. NPxY motifs in integrin  tails are phosphorylated by Src family kinases
which excludes integrins from focal adhesion and downregulates the cell adhesion
(Wennenberg et al., 2000; Datta et al., 2002). Tails containing non-phosphorylatable
NPxF motifs reverses the phenotype by retaining talin binding activity and integrin
activation (Law et al., 1998). Structural studies support this mechanism that talin PTBintegrin NPxY interaction occurs only through acidic and hydrophobic interactions,
because talin PTB lacks positively charged residues for binding to phosphorylated Tyr
side chains of 3 tail (Garcia-Alvarez 2003). Also, the affinity of the talin PTB for
phosphorylated 3 tail peptide is reduced compared to unphosphorylated one (Oxley et
al., 2008), which is consistent with disruption of integrin binding by phosphorylation.
Therefore, integrin phosphorylation may be a negative regulator of integrin activation by
maintaining an inhibitory complex on inactive integrin tails or by blocking talin binding
directly.
Recent studies show that autoinhibition and phosphorylation are not the only
possible mechanisms, and talin is the final but not the only regulator of integrin
activation. Kindlin family of proteins also binds to integrin tails, and talin depends on
kindlins to increase integrin activation (Ma et al., 2008; Moser et al., 2008, 2009).
However, how kindlin and talin cooperatively regulate integrin activation remains to be
determined.
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PART B. NMR SPECTROSCOPY IN STRUCTURAL BIOLOGY

General Overview of NMR Spectroscopy
NMR spectroscopy is an important complement to X-ray crystallography for
determining three-dimensional structures of proteins and nucleic acids at atomic level. In
1945, it was discovered that the energy levels of atomic nuclei are split by an applied
magnetic field. However, the field of NMR did not grow explosively until 1960 when
pulsed Fourier-transform NMR and consequently multidimensional NMR spectroscopy
are developed and applied in different disciplines such as chemistry and structural
biology. In consequent years, more technical developments partially minimized the
difficulties of NMR spectroscopy which result from low sensitivity of the technique and
from highly complex content of the NMR spectra. The sensitivity and resolution of the
NMR spectra (especially of extremely large molecules up to 1,000 kDa) are increased by
the introduction of new spectroscopy techniques such as TROSY and CRINEPT. Also,
progress in the theoretical and computational part of NMR, which includes computer
programs for automated-assignment of backbone, side chains, NOE constraints of the
proteins, leads to more efficient and faster utilization of information content of NMR
spectra. Importantly, rapidly developing recombinant protein expression and purification
techniques make easier and faster to study macromolecules such as large proteins and
supramolecular assemblies, and membrane proteins. Especially, the isotopic labeling of
proteins (uniformly or selectively) by the incorporation of isotopes such as 15N, 13C, 2H in
proteins simplifies the multidimensional NMR spectra drastically.
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The atomic nucleus has the intrinsic quantum property of spin. The overall spin of
the nucleus is determined by the spin quantum number. Only nuclei with non-zero spin
quantum number possess a magnetic moment and therefore are magnetically active. The
phenomenon of nuclear magnetic resonance occurs when the magnetic moment of an
atomic nucleus interacts with an external magnetic field and leads to a splitting of two
energy levels which are aligned either with or against the magnetic field. The difference
between the two energy levels is directly proportional to the gyromagnetic ratio of the
nucleus and the strength of the external magnetic field. Therefore strong magnetic fields
are necessary for NMR spectroscopy. Today, the spectrometers use powerful magnets
having magnetic fields of 20T (tesla) (~900 MHz).

NMR spectroscopy is rapidly developed by the introduction of FT- NMR (Fourier
Transform-NMR) which uses radio frequency (rf) pulses of different shapes, and
durations in specifically-designed patterns or pulse sequences. In a pulsed NMR, the
sample is magnetized in an external magnetic field, and a short but relatively strong
radiofrequency is applied to all of the protons in the sample to excite them
simultaneously. As the excited protons relax to their equilibrium positions, the emitted
signal is recorded and collected by a computer and subjected to a Fourier transform
mathematical analysis. The resulting frequency domain spectrum shows signal intensity
as a function of frequency. In one dimensional NMR spectrum (especially for the
proteins), the spectra are too complex for interpretation since most of the signals overlap
with each other. The introduction of additional spectral dimensions (2D, 3D or 4D)
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simplifies the spectra drastically. Therefore the invention of multidimensional spectra
made a major impact on NMR spectroscopy and was awarded by a Nobel Prize.

Applications of NMR Spectroscopy in Structural Biology
In living organisms, most of the biological mechanisms are largely mediated by
protein-protein interactions, which lead to conformational and dynamical changes in the
proteins, and consequently chemical and physiological changes in the organism system.
NMR spectroscopy is a powerful and highly-developed technique to study these
biologically important macromolecules, and their interactions at the atomic resolution.
Parallel developments of both multidimensional heteronuclear NMR experiments, and
isotope labeling techniques enhanced the determination of solution structures of proteins
and protein complexes up to a total molecular mass of 82kDa (Tugarinov et al., 2005).

The solution state of proteins is used in NMR experiments and that is particularly
suitable for the proteins which do not provide diffraction quality crystals in X-ray
crystallography. Most of NMR experiments can be carried out under similar conditions
(similar pH, temperature, or solution) as the physiological conditions to study structurefunction relationships of proteins whereas some crystal structures are determined under
exotic solution conditions required for crystallization. Moreover, the fastest and relatively
inexpensive 1H-15N HSQC NMR experiment rapidly shows disordered or well-folded
proteins on the NMR spectra and with which different protein constructs and solution
conditions can be tested to improve protein folding. In addition, “foldedness” criteria and
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crystallizability may be in correlation, so the data from HSQC experiment might help to
construct new protein boundaries for crystallographic analysis.

NMR spectroscopy is not solely used for structure determination of
macromolecules. It is also an excellent tool to quickly identify the binding interfaces of
protein complexes using chemical shift perturbation mapping. This NMR approach works
perfectly for weak protein-protein interactions (Kd ≤ 10-6); whereas to study the weakly
bound protein complexes is very difficult in X-ray crystallography. In addition to binding
analysis, another NMR approach, nuclear relaxation measurements are used to study
protein dynamics which generally affect the mechanism of molecular function.
Importantly, recent NMR application, transverse relaxation-optimized spectroscopy
(TROSY), has opened the door to study larger proteins up to 1,000 kDa, more membrane
proteins in detergent micelles, and larger oligonucleotides and their complexes with
proteins.

Protein Structure Determination by NMR Spectroscopy

1. Sample Preparation
2. Data collection / Processing of NMR spectra
3. Sequential Backbone and Side-chain Assignment
4. Collection of Structural Constraints
5. NMR Structure Calculation
6. NMR Structure Refinement
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The determination of NMR solution structure may be divided into six major steps,
and each step will be explained briefly. At the first step, highly pure (≥90% purity) and
usually ~250 ml of 1mM protein solution is prepared. If the molecular mass of the protein
is greater than 10 kDa, protein labeling with 13C and 15N isotopes is required to prevent
overlapping peaks on the spectra. To prepare such double-labeled protein, protein is
expressed in M9 minimal media instead of LB media, and
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NH4Cl and

13

glucose are

added into this media as nitrogen and carbon sources. As a second step, the sample is
placed in NMR machine and a series of multidimensional NMR experiments are
recorded, typically at temperatures 25 oC to 30oC. These data are processed by computer
programs to get the NMR spectra. At the third step, backbone and side chain residues of
the protein are sequentially determined using the spectra of triple resonance experiments.
There are a lot of different triple resonance experiments which can not be covered in this
short introduction. HNCA experiment which is a prototype for all triple resonance
experiments is shown below. In HNCA spectra, the nitrogen atom of a given amino acid
is correlated with C of its own and C of the preceding amino acid after the
magnetization is transferred between 1H-15N-C atoms.

HNCA
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1

HNi – 15Ni – 13Ci

1

HNi – 15Ni – 13Ci-1

Using more triple resonance experiments like HNCA, both backbone and side-chain
residues of whole amino acid sequence can be established, just like building a chain of
dominoes. At the forth step, more experimental constraints from various NMR
experiments (such as NOE for determining of interproton distances, RDC for determining
relative orientation of protein parts) are used to calculate 3D NMR structure. The double
arrow between 4th and 5th steps on the scheme indicates that NMR structure calculation
is repeated many times using the analysis of structural constraints at the 4th step until
most of the experimentally derived constraints is in agreement with a bundle of protein
conformations. Finally, a family of calculated structures instead of one defined structure
is refined to get a final ensemble.

1

H-15N Heteronuclear Single Quantum Spectroscopy (HSQC)
HSQC is a two-dimensional NMR experiment that correlates the
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N frequency

(chemical shift) with the directly attached 1H.

When 15N-labeled protein sample is used, 1H-15N HSQC provides the chemical shift
correlation of amide group15N with its directly attached amide proton (1HN) for each
amino acid of that protein (Figure 1.3.). In addition to backbone amide protons, the peaks
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from NH2 groups of the side chains of Asn, Gln and the aromatic 1HN protons of Trp and
His are observed on the HSQC spectrum. Theoretically, the Arg side chain peaks are also
observable on the spectrum; however, its side chain chemical shift value is outside of the
spectrum limits, its peaks are folded and therefore they generally appear as negative
peaks. Whereas, proline residues are not seen on the spectra since proline does not have
amide proton on its cyclic structure.

Figure 1.3. 1H-15N HSQC spectrum of a folded protein. The figure is adapted from this
website: www.protein-nmr.org/uk
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The position of each amino acid residue in the HSQC spectrum is dependent on the
chemical environment of each amide of the protein; therefore every folded protein has a
unique “fingerprint” pattern of peaks in the spectrum. Since chemical shifts are very
sensitive to the environment, small changes in pH, temperature or binding to other
molecules can induce chemical shift changes in the HSQC spectrum. For the
determination of NMR structures of the proteins, HSQC is the first performed NMR
experiment to check whether protein is well-folded or not, and whether have welldispersed peaks for further 13C, 15N and/or 2H double and/or triple-labeling of the protein
(which is expensive) for triple resonance experiments.

Chemical Shift Perturbation Map
The chemical shift perturbation mapping with HSQC experiment is the mostly used
NMR method to detect binding interfaces of the protein complexes since its relatively
short experiment time, high sensitivity and low sample (0.1-0.2 mM protein)
requirement.

The electrons in a molecule surround the nuclei and create a small magnetic field
which shields the nuclei slightly from the external magnetic field. Therefore, every
nucleus has a different chemical environment. This effect is called “chemical shift”. The
value of chemical shift (delta) in ppm (parts per million) is defined as:

Delta = ((wsignal-wreference)/wreference)*106
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The reference frequency for the ppm scale is defined as 0 ppm using the signal of
the methyl groups of tetrametylsilan (TMS). In protein NMR, a substance called DSS
(2.2-dimetyl-2-silapentane-5-sulfonic acid) is used equivalently.

Different chemical groups have different chemical shifts which are very sensitive to
the environment. This property is the major information source for NMR experiments. In
proteins, for example, the signals of amide protons, aromatic and aliphatic protons can be
distinguished by their chemical shifts, and these chemical shifts can be perturbed by
changing their chemical environments.

In chemical shift perturbation mapping with 1H-15N HSQC method, one protein is
labeled with
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N-isotope, and unlabeled binding partner is titrated into a solution of the

labeled protein. The chemical shift values of

15

N and 1HN is changed upon addition of

unlabeled binding partner if any interaction occurs, and these values are detected by
NMR and used to map the binding interface. Only the residues whose chemical
environment changes due to participating in binding or due to binding-induced
conformational rearrangements change their chemical shifts, whereas the residues that are
neither on the binding interface nor close proximity to the binding interface do not
change their chemical shifts.

When protein A interacts with protein B, the binding is always in equilibrium
between free and bound states, and this is defined as:
A + B ↔ AB

Kd= [AB]/ [A]*[B]
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In binding analysis by HSQC experiment, two sets of peaks appear in the HSQC
spectrum: one set belongs to the free protein, and the other to the bound protein. When
the binding is weak, the exchange rate between free and bound states is very fast,
therefore only one peak is observed for each residue and its position is the averaged
frequencies of the two states on the NMR spectra. In weak protein-protein interactions,
small chemical shift changes occur and hence the binding interface can be qualitatively
measured using the values of all perturbed and unperturbed residues if the assignment of
the free protein is available. Also, equilibrium constant (Kd) can be estimated from the
titration of

15

N-labeled protein with its unlabeled binding partner. The strong protein-

protein interactions often cause significant conformational and chemical shift changes.
The exchange rate between free and bound states is slow in strong bindings, therefore
averaged frequencies of two states cause broader peaks or completely to be disappeared
on the NMR spectra, which makes the analysis of the interface less straightforward as in
the fast exchange.

Transverse relaxation optimized spectroscopy (TROSY)
NMR spectroscopy is a powerful and useful method to study the structure
determination of proteins that are difficult to crystallize, to map the binding interfaces of
protein complexes, and to study intramolecular dynamics in macromolecules, reaction
kinetics, and protein folding. However, NMR spectroscopy has been limited to small
proteins (less than 25kDa) because of two main problems: First, large proteins and
macromolecular assemblies have large number of resonances which causes overlapping
peaks on the spectra, and this makes the analysis of the spectra very difficult. Second, in
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large proteins, the NMR signal relaxes faster, which means there is less time to detect the
signal. This in turn causes the peaks to become broader and weaker, and eventually to no
NMR signals at all. The limitation caused by overlapping peaks can be overcome by the
introduction of isotope-labeling and multidimensional experiments and the limitation
caused by transverse relaxation has been alleviated by a new technique called TROSY
(Pervusin et al, 1997). The introduction of TROSY has made possible to study very large
molecules and supramolecular assemblies like 900kDa chaperone GroES-GroEL
complex (Fiaux et al., 2002).

The application of NMR to large proteins is normally limited by the fact that the
width of the resonance lines in the spectrum is inversely proportional to the size of the
protein. Larger proteins have slower tumbling times and consequently cause shorter
relaxation times (T2). In other words, the NMR signal from larger molecules decays
faster, and this results in weaker signal and broader lines in the NMR spectrum (Figure
1.4). Using TROSY, the effective relaxation can be reduced, enabling improved spectral
resolution and improved sensitivity for large molecules. Technically, TROSY requires
high magnetic fields to suppress transverse relaxation, and better sensitivity can be
achieved using at least 700 MHz NMR machine for a 15-20 kDa protein. The full
potential of TROSY can be enhanced by deuteration of large proteins.

Deuterium, also called heavy hydrogen, is a stable isotope of hydrogen. The
deuterium contains one proton and one neutron in the nucleus, whereas common
hydrogen nucleus contains no neutron. Therefore, deuterium has a different magnetic
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moment from hydrogen, and deuterium oxide (D2O) or heavy water is used in NMR
spectroscopy frequently. Heavy water is not radioactive, and has physical properties
similar to water except being 11% more dense. Small concentrations of heavy water are
nontoxic for eukaryotes and bacteria can grow slowly in pure heavy water. In partially
(70%-90%) or fully deuterated proteins, hydrogen source is exchanged with deuterium
atoms, and when purified proteins are dissolved in H2O solutions, only amide (NH)
groups replace deuterons with protons. In this way, deuterated

groups does not

contribute to the NMR signal at the hydrogen frequency, and only protonated amide
groups are observed by NMR which attenuates the relaxation rate and eventually
improves spectral quality.
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Figure 1.4. NMR spectroscopy with small and large molecules in solution (a) The NMR
signal obtained from small molecules in solution relaxes slowly; it has a long transverse
relaxation time (T2). A large T2 value translates into narrow line widths (∆ ) in NMR
spectrum after Fourier Transformation of the NMR signal. (b) By contrast, for larger
molecules, the decay of the NMR signal is faster (T2 is smaller). This result both in a
weaker signal measured after the NMR pulse sequence and in broad lines in the spectra.
(c) Using TROSY, the transverse relaxation can be substantially reduced, which results in
improved spectral resolution and improved sensitivity for large molecules. Figure and
legend is adapted from Fernandez et al., 2003
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ABSTRACT
Activation of heterodimeric (/) integrin transmembrane receptors by the 270 kDa
cytoskeletal protein talin is essential for many important cell adhesive and physiological
responses. A key step in this process involves interaction of phosphotyrosine binding
(PTB) domain in the N-terminal head of talin (talin-H) with integrin  membraneproximal cytoplasmic tails (-MP-CTs). Compared to talin-H, intact talin exhibits low
potency in inducing integrin activation. Using NMR spectroscopy, we show that the large
C-terminal rod domain of talin (talin-R) interacts with talin-H and allosterically restrains
talin in a closed conformation. We further demonstrate that talin-R specifically masks a
region in talin-PTB where integrin -MP-CT binds and competes with it for binding to
talin-PTB. The inhibitory interaction is disrupted by a constitutively activating mutation
(M319A) or by phosphatidylinositol 4,5-bisphosphate, a known talin activator. These
data define a distinct autoinhibition mechanism for talin and suggest how it controls
integrin activation and cell adhesion.

INTRODUCTION
Talin is a high molecular weight protein containing an N-terminal head (1–433,
talin-H, 50 kDa) and a C-terminal rod domain (434– 2541, talin-R, 220 kDa) (Figure
2.1A) (Rees et al., 1990). Talin-H is globular, containing a FERM domain composed of
three lobes, F1, F2, and F3 or phosphotyrosine-binding (PTB) domain (Garcia-Alvarez et
al., 2003); talin-R is highly elongated, containing a series of helical bundles separated by
linkers (McLachlan et al., 1994; Papagrigoriou et al., 2004; Fillingham et al., 2005;
Gingras et al., 2008). Discovered in high concentrations at regions of cell-substratum
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contact (Burridge and Connell, 1983), talin has long been known to be a physical linker
between integrins and the actin cytoskeleton, and a regulator of a variety of cellular
processes such as cell spreading, migration, and proliferation (Turner and Burridge, 1991;
Calderwood et al., 2000). Recent advances have revealed an additional and especially
important role for talin: by binding to integrin  CTs, talin induces high affinity ligand
binding to integrins, integrin activation (Tadokoro et al., 2003; Wegener et al., 2007), a
major

step

in

cell

adhesion,

migration,

and

numerous

physiological

and

pathophysiological responses (for review, see Hynes, 2002). A surge of genetic, cell
biological, and biochemical experiments has now established that talin F3, the PTB
domain of talin-H, plays a dominant role in inducing the integrin activation (Calderwood
et al., 2002; Tadokoro et al., 2003; Ma et al., 2006; Wegener et al., 2007). Structural
analyses have shown that talin-PTB binds to both membrane-distal and membraneproximal regions of integrin  CTs (Vinogradova et al., 2002, 2004; Garcia-Alvarez et
al., 2003; Ulmer et al., 2003; Wegener et al., 2007), and the latter event causes integrin
activation by unclasping the integrin / CT complex (Vinogradova et al., 2002, 2004;
Kim et al., 2003; Wegener et al., 2007).

With rapidly accumulating in vitro (see review, Calderwood, 2004) and in vivo
(Nieswandt et al., 2007; Petrich et al., 2007) data demonstrating the central role of talin in
integrin activation, a fundamental question still remains: how is talin activity regulated?
Previous functional analyses have suggested that talin activity may be autoinhibited for
binding to integrins (Martel et al., 2001; Yan et al., 2001). However, this mechanism
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remains largely speculative, and the structural basis for such autoinhibition and how it
impacts integrin activation have not been established.

Here, we use structural, biochemical, and mutational analyses to pinpoint the
molecular details of the talin regulation. Intact talin, but not its talin-H fragment, has low
intrinsic integrin activating activity, directly supporting the notion that talin adopts a
default inactive conformation. By performing extensive NMR-based structural analyses,
we show that a middle segment of talin-R specifically interacts with talin-FERM and
competes with integrin  CT for binding to talin-PTB. Mutations of key residues in talinPTB involved in binding to integrin  CT revealed that talin-R specifically masks the
integrin membrane-proximal  CT-binding site on talin-PTB that is key for controlling
the cytoplasmic unclasping and activation of integrins. A structure-based mutation on
talin-PTB, which does not affect talin-H/integrin interaction but disrupts the talin-H/talinR interaction, leads to constitutive activation of full-length talin. Phosphotidylinositol
4,5-bisphosphate (PIP2), a known talin activator (Martel et al., 2001), disrupts the
inhibitory talin-PTB/talin-R interaction. These results define a structural mechanism of
the talin autoinhibition and suggest how it may serve as a specific cellular brake to
control integrin activation.

MATERIALS AND METHODS
Sample preparation for NMR analyses: A pET15b vector containing a thrombincleavable N-terminal His-tag GSS(H)6SSGLVPRGSHM was used to subclone the talin-H
fragments, talin-F3/PTB (306-405), talin-F2F3 (206-405). A variant of pET15b, pET30a,
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was used to clone larger talin-R fragments, talin-R 434-947 (R1), 944-1483 (R2), 14831653 (R3), 1654-1848 (R4), 1841-1983 (R5), 1984-2102 (R6), 2103-2229 (R7), 22252344 (R8), 2338-2541 (R9), and talin-RM (1654-2344). A construct 1984-2344
encompassing R6-R8 was also made in the same way. The fragments were expressed in
E. coli BL21 (DE3), and the cells were harvested and lysed using 10mg/ml lysozyme. All
fragments were purified using nickel columns and 250mM imidazole in elution buffer
(300 mM phosphate, 500 mM NaCl, pH 8.0). The eluted proteins were dialyzed with
phosphate buffer (50 mM phosphate, 150 mM NaCl, 1 mM DTT, pH 7.0), and the Histags were cleaved using thrombin. The proteins were then further purified by size
exclusion chromatography on Superdex-200 (Amersham Bioscience). Talin-H was
prepared as described before (Vinogradova et al., 2002).

To prepare

15

N and/or

13

C-labeled protein, the cells were grown in M9 minimal

media containing 15NH4Cl and/or 13C-glucose, and all other conditions were the same as
for preparing the unlabeled proteins. To prepare 15N/90%2H-labeled talin-PTB, cells were
grown in M9 minimal media containing 15NH4Cl and 90% 2H2O. Point mutants of talinPTB (M319A, L325R, W359A, S365D, S379R, and Q381V) were made using a
QuickChange site-directed mutagenesis system (Stratagene, Inc) and prepared in the
same way as the wild-type proteins. A point mutation (C336S) was also introduced in
talin-PTB as reported previously (de Pereda et al., 2005) to improve protein stability.

The 3 CT chimera peptide TIHDRKEFAKFEEERARAKWVYSPLHYSAR (the
sequence in bold is PIPKI tail), 3 CT chimera mutant (F730A), and PIPKI
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(SWVYSPLHYSAR) were synthesized by our Biotechnology Core facility. For
improved solubility, the KLLI sequence was not included at the N-terminus of the 3 CT
since it is not involved in interacting with talin-PTB (Wegener et al., 2007). The 3 CT
chimera binds tightly to talin-PTB (Kd~140 nM) in slow exchange, which was shown to
mimic the 3 CT that has weaker binding to talin-PTB in intermediate exchange
(Wegener et al., 2007).

NMR spectroscopy: All heteronuclear NMR experiments were performed as
described by Bax and Grazsiek, 1993. All triple resonance NMR experiments for 1mM
talin-F2F3 were performed on a Varian 600 MHz instrument equipped with a triple
resonance probe and shielded z-gradient unit. These experiments were performed at
25oC, pH 7.0, in 150mM NaCl, 50 mM phosphate buffer, 1mM DTT. All HSQC-based
experiments were performed on either Bruker Avance 600 or 900 MHz spectrometers
using the cryogenic triple resonance probes.

15

N-labeled and/or 15N/90%2H-labeled talin-PTB or talin-F2F3 (0.2 mM) was used

with and without the talin-R fragments at 1:2 ratio in all HSQC experiments. For
chemical shift mapping, TROSY-based HSQC (Pervushin et al., 1997) for talin-PTB or
talin-F2F3 in complex with talin-RM were performed on a Bruker 900 MHz spectrometer
equipped with a cryogenic triple resonance probe. Weighted chemical shift changes were
calculated using the equation: Δobs[HN,N]=([ΔHNWHN]2+[ΔNWN]2)1/2, where WHN=1 and
WN=0.154 are weighting factors based on the gyromagnetic ratios of 1H and 15N. All the
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spectra were processed with nmrPipe (Delaglio et al., 1995) and visualized with PIPP
(Garrett et al., 1991).

Surface Plasmon Resonance (SPR) Measurements: SPR analysis was performed
using a BIA Core 3000 instrument (Amersham Pharmacia Biotech). CM5 sensor chips
were activated using the amine coupling kit from Amersham Pharmacia Biotech. TalinRM was then immobilized to the activated surface. Talin-PTB and its mutants were each
injected at the concentration range 0.1-5 μM and the flow rate was 20µl/min. For
PIP2/talin-H interaction, biotinylated C6-PIP2 (C-45B6a, echelon Biosciences, Inc) was
immobilized to a biotin chip and talin-H was injected at 20µl/min. The surfaces of the
sensor chips were regenerated by injection of 20mM NaOH. Experiments were performed
at 25oC in 10 mM Hepes buffer, pH 7.4. All binding affinities were calculated using the
BIAcore 3000 evaluation software (Biacore AB, Uppsala, Sweden).

Plasmids and transfections: The plasmid DNA encoding full-length mouse talin
was kindly provided by Richard Hynes, MIT, and it was cloned into pEGFP-N1 vector
(Clontech Lab, Inc) encoding a red-shifted variant of wild-type GFP using EcoRI and
AgeI restriction sites. The final DNA had a C-terminal GFP fusion and was confirmed by
sequencing. The full length talin M319A DNA mutant was prepared employing the
QuickChange Site-Directed Mutagenesis Kit (Stratagene) using the cloned GFP-fusion
talin DNA as a template. The resulting mutant DNA was also confirmed by sequencing.
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Integrin activation: The effects of full-length talin, full length talin M319A, and
talin-H on integrin activation were analyzed using CHO cells stably expressing integrin
(IIb3-CHO) and an activation-specific anti-IIb3 mAb (PAC1) as described previously
(Ma et al., 2008) Briefly, IIb3-CHO cells were transfected with EGFP-talin, EGFPtalin-H or EGFP vector alone as a control. Twenty four hours after transfection, the cells
were harvested and stained with PAC1 followed by incubation with Alexa Fluor® 633
goat anti-mouse IgM conjugate. After washing, the cells were fixed and analyzed by flow
cytometry on a FACSCalibur instrument (BD Scientific, Franklin Lakes, NJ). The PAC1
binding was analyzed only on a gated subset of cells positive for EGFP expression. The
mean fluorescence intensities of PAC1 bound to the EGFP-talin or EGFP-talin-H
expressing cells were compared to that of PAC1 bound to the control EGFP expressing
cells. Three independent experiments were performed. T-student test was used for
statistical analyses. p values <0.05 were considered statistically significant.

RESULTS
Talin adopts a default low active state for regulating integrin activation
It has been shown extensively that talin-H can activate integrins (Calderwood et al.,
1999, 2002; Tadokoro et al., 2003; Kim et al., 2003; Ma et al., 2006; Bouaouina et al.,
2007), and it is presumed that this activity is substantially blunted in full length talin. To
directly compare the integrin activating activity of these two talin forms, we transfected
vectors expressing full length talin or talin-H, all as EGFP constructs, into a CHO cell
line stably expressing integrin IIb3 (IIb3-CHO). The activation state of the IIb3 was
then measured based on the binding to activation-specific anti-IIb3 antibody (PAC1).
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Figure 2.1. Effects of Full-Length Talin and Talin-H on Integrin Activation. (A) Domain
organization of full-length talin. The three lobes of talin-H FERM domain F1, F2, F3 or
PTB and rod domain have been labeled. (B) Comparison of the activation of integrin
IIb3 by full-length talin and talin-H. CHO cells stably expressing the integrin IIb3
were transfected with cDNAs for full-length talin or talin-H, each as EGFP constructs.
The EGFP positive cells were gated and used to monitor PAC-1 binding to determine the
extent of IIb3 activation as previously described (Ma et al 2008,). The data are means ±
S.D. from three independent experiments. **P<0.01.
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To eliminate the influence of varied expression levels for talin-H and full length talin, only
EGFP positive cells with similar expressions were gated for FACS analysis. The data
summarized in Figure 2.1 are taken from three independent experiments and show that while
talin-H induced substantial activation of IIb3 activation, full-length talin was significantly
weaker as an activator. Thus, our data provide direct functional evidence for the supposition
that the integrin activation by full-length talin is dampened and is enhanced by events that
change exposure of its head region.

A middle segment of Talin-R (1654-2344) interacts with talin-PTB in talin-FERM
Since talin-PTB (F3) in talin-H is solely responsible for binding to integrin  CTs
during integrin activation (Calderwood et al., 2002; Garcia-Alvarez et al., 2003;
Tadokoro et al., 2003; Wegener et al., 2007), we reasoned that talin-R might mask the
integrin  CT binding site on talin-PTB, thereby preventing the talin-PTB function. To
test this hypothesis, we set out to use NMR-based 2D 1H-15N HSQC (heteronuclear single
quantum correlation) experiment to examine the interaction between

15

N-labeled talin-

PTB and unlabeled talin-R fragments. 2D 1H-15N HSQC is known to be an extremely
sensitive technique for probing protein-target interactions with a wide range of affinities
(Bonvin et al., 2005; Vaynberg and Qin, 2006; Takeuchi and Wagner, 2006).

The HSQC spectrum of a 15N-labeled protein contains many peaks, each of which is
a correlation of a proton to its attached

15

N within a particular residue in the protein.

Some peaks may be shifted or broadened in the HSQC spectrum if the protein is bound to
a target, which is an excellent indication of the binding interface. The peak broadening or
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disappearance could be due to the size increase or intermediate rate exchange of the
protein complex at the NMR time scale. Our strategy was that if any of the unlabeled
talin-R fragments binds to

15

N-labeled talin-PTB, some or all 1H/15N amide signals of

talin-PTB should be perturbed and broadened, which in turn provides information on the
intramolecular interaction between talin-PTB and talin-R. Based on the available helical
bundle structural information on talin-R (Papagrigoriou et al., 2004; Fillingham et al.,
2005; Gingras et al., 2008) and a secondary structure prediction program (Bryson et al.,
2005), we then dissected talin-R into nine consecutive fragments (R1:434-947, R2:9441483, R3:1482-1653, R4: 1654-1848, R5: 1841-1983, R6: 1984-2102, R7: 2103-2229,
R8:2225-2344, and R9: 2338-2541), where the division regions were predicted to be
random coil or loop structures so the structural integrities of these fragments should be
preserved. A series of HSQC spectra were collected for 15N-labeled talin F2F3 domain,
which contains talin-PTB (F3), in the absence and presence of individual unlabeled talinR fragments. Starting from the N-terminus of talin-R, we found that R1, R2, R3 had little
effect on the HSQC spectrum of talin-F2F3 (Figure 2.2.A-2.2.C) whereas R4 (~21 kDa)
caused significant line-broadening on talin-F2F3 (~22 kDa) (Figure 2.2.D), suggesting
that R4 binds to talin-F2F3. From the C-terminus, R9 did not bind (Figure 2.2.E) but R8
caused significant line-broadening of talin-F3F3, suggesting that it also interacts with
talin-F2F3 (Figure 2.2.F). These initial mapping data indicated that talin-R does interact
with talin-F2F3 and the binding site appears to involve multiple regions including R4 and
R8 but not the N-terminal R1-R3 and C-terminal R9. Based on these initial data, we then
prepared another larger expression construct encompassing R4 and R8, i.e., 1654-2344
with a total molecular weight of ~76 kDa (termed talin-RM), which is well-folded as
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Figure 2.2. The Interaction between
Fragments. 2D 1H-15N HSQC of

15

15

N-Labeled Talin-PTB and Unlabeled Talin-Rod

N-labeled talin-F2F3 in the presence (black) and

absence (red) of (A) talin rod (R1:434-947) (B) talin rod (R2: 944-1483); (C) talin rod
(R3:1482-1657); (D) talin rod (R4:1654-1848); (E) talin rod (R9: 2338-2541); and (F)
talin rod (R8: 2225-2344.
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assessed by its chemical shift dispersion pattern in the TROSY HSQC spectrum (Figure
2.3.). As predicted, talin-RM also bound to talin F2F3, as indicated by the substantial linebroadening and disappearance of talin F2F3 signals in HSQC (MW~100 kDa) (data not
shown). By employing TROSY technique (Transverse Relaxation Optimized
Spectroscopy) into HSQC, which is tailored for detecting NMR signals of large proteins
and protein complexes (Pervusin et al., 1997), we were able to recover majority of the
signals, some of which were significantly shifted due to binding (Figure 2.4.A).
To further understand the nature of this interaction, we performed backbone signal
assignment of talin F2F3 using triple resonance NMR experiments, including HNCACB,
CBCACONH, HNCA, HNCO, HC(CO)NH, and C(CO)NH (Bax and Grazsiek, 1993).
Table A1 (see the appendix) lists the chemical shift assignments of this construct.
Chemical shift mapping revealed that only NMR signals of F3 (PTB) but not F2 in talin
F2F3 were either significantly shifted or broadened (Figure 2.4.B), thus supporting our
hypothesis that talin-PTB is responsible for binding to talin-RM. To improve the spectral
quality and to simplify the spectral analysis, we made

15

N/2H-labeled talin-PTB and

performed its TROSY-HSQC in complex with the unlabeled talin-RM (total complex is
~90 kDa). Both deuteration and TROSY are known to dramatically reduce the linebroadening of the proteins, which led to an excellent and well-resolved spectrum of talinPTB bound to unlabeled talin-RM (Figure 2.5.A). As expected, talin-RM caused
significant chemical shift perturbation for talin-PTB (Figure 2.5.A). Surface plasmon
resonance (SPR) experiment revealed that the dissociation constant (KD) between talinPTB and talin-RM is ~577 nM (Table 2.1 and Figure 2.5.B).
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Figure 2.3. The TROSY HSQC Spectra of Talin-RM. The signals are wellspread with a
significant number of peaks resonating at 1H>9ppm and <7.5ppm, which are indications
of well-folded proteins. Note that unfolded proteins are known to have congested
chemical shift dispersion with all signals resonating in the narrow 1H spectral window
(7.5-8.5 ppm). The sample concentration was 0.3 mM, and the data were acquired for 21
hours.
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Figure 2.4. The binding of talin-RM to talin-F2F3. (A). 2D TROSY 1H-15N HSQC of
talin-F2F3 in the absence (black) and presence of unlabeled talin-RM (red). Well resolved
peaks, which are either significantly broadened or shifted, are labeled in the free form
talin-F2F3. (B) Chemical shift mapping of the binding to talin-F2F3. Only the resonances
in F3 (306-405) are significantly perturbed. Signals that are diminished due to severe
line-broadening are colored in grey.
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Figure 2.5. The Interaction of Talin-PTB with Talin- RM. (A). 2D TROSY 1H-15N
HSQC of 15N/90%2H-labeled talin-PTB in the absence (black) and presence (red) of
talin-RM. Significantly shifted peaks are labeled. The inset shows a representative peak
that is shifted in the presence of talin-RM at 1:0.0 (black), 1:0.5 (pink), 1:1.0 (Cyan), and
1:2 (red) ratios.
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Figure 2.5. (continued) Talin-PTB/talin-RM interaction (B) SPR measurement for the
talin-PTB interaction with talin-RM. The dissociation constant (KD) between talin-PTB
and talin-RM is 577 nM (Table 2.1). The affinities for other mutants measured are in
Table 2.1.
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Talin-RM and integrin membrane-proximal 3 CT compete for binding to an
overlapping binding site on talin-PTB
To precisely map the talin-RM binding site on talin-PTB, we performed a series of
NMR titration experiments. The TROSY-HSQC spectra were collected for the

15

N/2H-

labeled talin-PTB in the absence and presence of increasing concentrations of talin-RM to
obtain molar ratios of 1:0.0, 1:0.5, 1:1.0, and 1:2. This experimental design allowed us to
trace the significantly perturbed signals (Figure 2.5.A). Figure 2.6.A shows the detailed
chemical shift perturbation profile. Remarkably, the perturbation pattern was found to be
similar to the previously reported one by integrin 3 CT or integrin membrane-proximal
3 CT segment fused to PIPKI peptide (Wegener et al., 2007) (Figure 2.6.A), suggesting
that the talin-RM binding site on talin-PTB overlaps with that for integrin 3 CT.

Interestingly, chemical shift mapping revealed that talin-R4 (1654-1848) also
induced very similar perturbation profile (Figure 2.7.A vs 7B), albeit with slightly
reduced chemical shift changes and lower affinity (KD~3.6M, Table 2.1) than talin-RM
(KD~0.58M, Table 2.1). On the other hand, a larger fragment containing C-terminal
talin-RM (R6-R8, 1984-2344), induced different and very narrow-range of chemical shift
changes peaking around 367-375 (Figure 2.7.C) with much lower affinity (KD~78.0M,
Table 2.1) than talin-RM. Combining these two fragments in a single construct (talin-RM),
however, yields higher affinity (0.58M, see Table 2.1). These data suggest that R4 and
R6-R8 synergistically bind to different regions in talin-PTB and that R4 plays more
important role in binding to talin-PTB (see more data below). Figure 2.6.B highlights
significantly shifted residues in talin-PTB upon binding to talin-RM and integrin 3 CT
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Figure 2.6.. Mapping of the talin-RM binding site on talin-PTB. (A) 1H/15N Chemical
shift changes of talin-PTB upon binding to talin-RM as a function of residue number. As a
comparison, the chemical shift changes of talin-PTB upon binding to 3 CT chimera is
also reproduced using the chemical shift table deposited in the BioMagResBank
(accession number 7150) by Wegener et al., 2007. The membrane-distal residues
involved in binding to integrin 3 CT chimera are colored in red in the upper panel. Note
that W359 changed dramatically by 3 CT chimera (the change was so big due to its
bulky interaction with talin-PTB (Wegener et al., 2007). that a broken line was used to
conserve space).
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Figure 2.6. (continued) Mapping of the talin-RM binding site on talin-PTB. (B)
Significantly perturbed residues on talin-PTB by 3-CT chimera (left) and talin-RM
(right) are highlighted using the structure of talin-PTB. The order of dark blue, blue, and
light blue indicate the extent of the chemical shift changes with the dark blue having the
most significant changes. The changes have some similarity indicating potential
overlapping binding site for 3 CT and talin-RM but there are significant differences
indicating the binding sites are not identical.
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Figure 2.7. Chemical shift changes of talin-PTB in the presence of (A) talin-RM, (B)
talin-R, (C) talin-R6-R8. Talin-R4 shows very similar perturbation pattern as talin-RM
whereas talin-R6-R8 has very narrowly perturbed region peaking at 367-378. Talin-R6R8 binds weaker than talin-R4 to talin-PTB (see Table 3.1) but the combined talin-R4
and talin-R6-R8 in a single talin-RM construct produces much higher affinity (see Table
3.1) suggesting that talin-R4 and talin-R6-R8 bind to different regions.
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chimera, respectively, thus providing more direct view of how the two binding sites
might overlap.

To more precisely evaluate how the integrin 3 CT binding sites on talin-PTB may be
involved in binding to talin-RM, we introduced a series of structure-based talin-PTB point
mutations L325R, W359A, S365D, S379R, Q381V, each of which has been previously
shown to impair the talin-mediated integrin activation without affecting the structural
integrity of talin-PTB (Wegener et al., 2007). L325R, S365D, S379R, and Q381V
disrupted the integrin  membrane-proximal CT binding to talin-PTB whereas W359A
abolished the integrin CT binding to talin-PTB by removing the bulky interaction of the
membrane-distal CT with talin-PTB (Wegener et al., 2007). We also made M319A
mutant. M319 is a surface-exposed hydrophobic residue that is not involved in interacting
with either integrin 3 membrane-proximal region (Wegener et al., 2007) or membranedistal region (Garcia-Alvarez et al., 2003), and thus its mutation to Ala had little effect on
the interaction with integrin 3 CT chimera (Figure 2.8.). However, M319 is most
significantly perturbed by talin-RM (Figure 2.6.A), suggesting that it may play a crucial
role in interacting with talin-RM. Table 2.1 summarizes the KD values of talin-RM binding
to wild type talin-PTB, M319A, L325R, W359A, S365D, S379R, and Q381V as derived
from SPR. As compared to the wild type talin-PTB, S365D, S379R, and Q381V
exhibited markedly reduced binding to talin-RM, whereas L325R had very small effect.
As expected, while M319A still binds to integrin 3 CT as wild-type talin-PTB (Figure
2.8.A vs 8.B), it had dramatically weakened interaction (~140 fold) with talin-RM and
slightly weakened the interaction with talin-R4 (~10 fold) (Table 2.1).
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Table 2.1. KD of the talin RM or smaller fragments binding to talin-PTB and talin-PTB
mutants

Protein

Target

KD (M)a

WT talin-PTB

Talin-RM

(5.77±1.35)x10-7

WT talin-PTB

Talin-R4

(3.60±0.29)x10-6

WT talin-PTB

Talin-R6-R8

(7.80±1.88)x10-5

PTB M319A

Talin-RM

(8.09±2.38)x10-5

PTB M319A

Talin-R4

(4.23±1.32)x10-5

PTB L325R

Talin-RM

(6.67±1.32)x10-7

PTB W359A

Talin-RM

(5.29±1.39)x10-7

PTB S365D

Talin-RM

(1.66±0.50)x10-3

PTB S379R

Talin-RM

(6.25±1.55)x10-4

PTB Q381V

Talin-RM

(3.14±0.80)x10-4

a. All binding affinities were calculated by two independent measurements
using the BiaCore 3000 evaluation software (BiaCore AB, Uppsala,
Sweden). 2 <10 were obtained for all the data, indicating good fit.
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Figure 2.8.: M319A binds to β3 CT chimera similarly as WT talin-PTB. (A) Overlay of
M319A in the absence (black) and presence (cyan) of β3 CT chimera; (B) Overlay of WT
talin-PTB in the absence (black) and presence (cyan) of β3 CT chimera, Comparison of
(A) and (B) shows that integrin β3 CT chimera induced the same chemical shift changes
for both M319A and WT talin-PTB.
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The effects of S365D, S379R, and Q381V recapitulate those for binding to the
integrin membrane-proximal 3 CT and indicate that this site significantly overlaps with
that for talin-RM in the talin-PTB domain. To further confirm this conclusion, we
prepared large quantities of two representative mutants in

15

N/2H-labeled form, S365D

(reduced binding to talin-RM by ~2.9x103 fold) and Q381V (reduced binding to talin-RM
by ~540 fold) (Table 2.1) and examined their chemical shift perturbation in the absence
and presence of unlabeled talin-RM. Consistent with the SPR data, the extent of the
chemical shift changes was decreased for Q381V and much more decreased for S365D as
compared to WT talin-PTB (Figure 2.9.).

Interestingly, W359A, which completely abolished the talin-PTB binding to
integrin 3 CT by disrupting the bulky hydrophobic interaction between talin-PTB and
membrane-distal 3 CT (Garcia-Alvarez et al., 2003; Wegener et al., 2007), had little
effect on the KD of the talin-PTB/talin-RM interaction (Table 2.1). This observation,
together with the above described effects of other mutants, suggested that the binding
sites on talin-PTB for talin-RM and integrin 3 CT are overlapping but not identical. To
further investigate this possibility, we performed HSQC-based competition experiments.
As shown in Figure 2.10.A and 10.B, while the majority of signals disappear from

15

N-

labeled talin-PTB upon binding to the large talin-RM (total MW~90 kDa, KD~577nM, see
Table 2.1), these signals return upon addition of equal molar 3 CT chimera (3
membrane-proximal CT fused to PIPKI peptide, MW~3.5 kDa, KD~140nM, see
Wegener et al., 2007), yielding a spectrum identical to that for

15

N-labeled talin-PTB

bound to the unlabeled 3 CT chimera (Figure 2.10.C). These data demonstrate that the
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Figure 2.9. Chemical shift perturbation profiles for the WT talin-PTB and its mutants
Q381V and S365D by talin-RM. Note that the chemical shifts are attenuated with the F3
Q381V but are still similar to WT, whereas chemical shifts are dramatically reduced with
the F3 S365D mutant.
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Figure 2.10. NMR-based competition experiments. (A) 2D 1H-15N HSQC of 0.2mM
15N-labeled talin-PTB. (B) The same talin-PTB in the presence of 0.4mM unlabeled
talin-RM. Majority of the signals disappeared as a result of large complex formation
(~90kDa). (C) The same talin-PTB in the absence (black) and presence (red) of 0.4mM
unlabeled talin-RM and 0.4mM β3 CT chimera. As compared to (B), addition of β3 CT
chimera recovered all the peaks leading to a spectrum identical to that for 15N-labeled
talin-PTB bound to the unlabeled β3-CT chimera (total MW~15 kDa), demonstrating that
the β3 CT chimera effectively displaced talin-RM from binding to talin-PTB. (D) The
same talin-PTB in the presence of 0.4mM unlabeled talin-RM and excess 0.8mM PIPKIγ
peptide. In contrast to β3 CT chimera, excess PIPKIγ peptide did not compete with talinRM.
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small 3 CT chimera peptide competed with large talin-RM for binding to talin-PTB. In
contrast, excess PIPKI peptide, which mimics the 3 membrane-distal CT binding and
binds tightly to talin-PTB (KD~270nM) (de Perera et al., 2005), did not recover the
broadened signals at all (Figure 2.10.D), indicating that PIPKI and talin-RM do not have
overlapping binding sites on talin-PTB. Since PIPKI mimics the 3 membrane-distal CT
for binding to talin-PTB (de Pereda et al., 2005; Kong et al., 2006; Wegener et al., 2007),
our NMR data are in agreement with our SPR data on W359A mutant (Table 2.1)
indicating that while the integrin membrane-proximal CT binding site is significantly
masked by the talin-RM, the 3 membrane-distal CT binding site for talin-PTB is not.
Consistently, a F730A mutant of the chimera peptide, which has dramatically reduced
membrane-proximal 3 CT binding to talin-PTB (Wegener et al., 2007), did not compete
effectively with talin-RM (Figure 2.11.A vs 11.B). Note that the 3 CT also binds to talinRM (Tremuth et al., 2004). However, such binding does not appear to interfere with the
talin-PTB/talin-RM interaction since 3 CT did not affect the talin-RM interaction with
talin-PTB W359A (Figure 2.12.). Note that W359A has the same affinity to talin-RM as
the WT talin-PTB (Table 2.1) but no binding to 3 CT (Wegener et al., 2007).

NMR-based competition experiments also revealed that talin-R4 (Figure 2.13.A)
but not talin-R6-R8 (Figure 2.13.B) competed with 3 CT chimera for binding to talinPTB. Since talin-R4 induced very similar chemical shift perturbation pattern as talin-RM
when binding to talin-PTB (Figure 2.7.), this finding suggests that talin-R4 plays a major
role in masking the membrane-proximal CT binding site on talin-PTB. It also further
supports our forgoing chemical shift mapping and affinity-based results that talin-R4 and
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Figure 2.11. Competition of β3 membrane-proximal CT and its mutant with talin- RM for
binding to talin-PTB. (A). HSQC of 0.2 mM 15N-labeled talin-PTB in the absence
(black) and presence (red) of 0.4 mM talin-RM and 0.6mM WT β3 CT chimera, showing
that WT β3 CT is very potent for competing with talin-RM for binding to talin-PTB,
generating a spectrum of talin-PTB/β3-CT chimera complex (red); (B). HSQC of 0.2 mM
15N-labeled talin-PTB in the absence (black) and presence of 0.4 mM talin-RM (red),
and presence of both 0.4 mM talin-RM and 0.6mM β3 CT F730A mutant chimera
(green). As compared to (A), β3 CT F730A mutant did not effectively compete with
talin-RM since majority of peaks are broadened (disappeared) as compared to WT β3 CT
chimera in (A) despite the fact that the spectra were collected at the same experimental
conditions.
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Figure 2.12. Talin-RM/β3 CT interaction does not affect the talin-RM/talin-PTB
interaction. (A) HSQC of W359A free form; (B) HSQC of 0.2mM 15N-labeled talinPTB W359A in the presence of 0.4 mM talin-RM (black) showing the disappearance of
signals due to the formation of the large complex with the same affinity as the WT talinPTB/talin-RM (Table 2.1). Addition of excess (1mM) of β3-CT fused to MBP (cyan) had
no effect on the spectrum.

57

58

Figure 2.13. Talin-R4 and Talin-R6-R8 bind to talin-PTB differently. (A) 1D trace of
selective signal G394 from HSQC of 0.2mM 15N-labeled talin-PTB in the free form
(black, see black arrow) and in the presence of 0.4mM Talin-R4 (red, see red arrow) and
Talin-R4:β3 CT chimera (0.4mM: 0.6mM) (blue, see blue arrow). Addition of Talin-R4
dramatically reduced the signal of talin-PTB G394 (see red arrow) due to line-broadening
of the complex but addition of β3 CT chimera resumed the signal intensity and shifted the
signal to the β3 CT bound position (see blue signal), indicating β3 CT chimera replaced
the talin-R4 from talin-PTB, showing that β3 CT chimera disrupted the talin-PTB/talinRM interaction. (B). The same 1D trace as (A) for 0.2mM 15N-labeled talin-PTB in the
free form (black) and in the presence of 0.4 mM Talin-R6-R8 (red, see red arrow) and
Talin-R6-R8:β3 CT chimera (0.4mM:0.6mM) (blue, see blue arrow). In contrast to (A),
β3 CT chimera had little effect on the talin-PTB/talin-R6-R8 interaction (the signal is
shifted by binding to β3 CT but still has the same height as that bound to talin-R6-R8).

59

talin-R6-R8 bind to different regions of talin-PTB. Figure 2.14.B summarizes the surface
depiction of the talin-PTB structure in which potential key residues directly involved in
binding to talin-RM are highlighted based on the chemical shift mapping, mutagenesis
and competition data. The binding surface is compared to that for the talin-PTB/integrin
 CT complex (Figure 2.14.A) (Wegener et al., 2007), which shows that the integrin
membrane-proximal 3 CT binding site significantly overlaps with that for talin-RM, thus
providing a view of how talin-R may sterically suppress the integrin  CT binding to
talin-PTB in the closed conformation of talin.
To further functionally evaluate the significance of the talin autoinhibition, we
examined the talin M319A activity in integrin activation. Since this mutant still maintains
the integrin binding (Figure 2.8) but has dramatically reduced the talin-PTB/talin-RM
affinity (Table 2.1), we speculated that the full length talin M319A could be
constitutively active in activating integrin. As shown in Figure 2.15., M319A indeed
dramatically enhanced talin induced integrin IIb3 activation as compared to the wild
type talin. Furthermore, such an enhancement could be abolished by incubation of RGDS
peptide, a ligand binding inhibitor for 3 integrins (data not shown), indicating its
specificity. Thus, this observation offers a very strong support for our hypothesis. Note
that the M319A-induced integrin activation is slightly more potent than talin-H. While
the precise mechanism for this higher potency remains to be determined, one can
envision two possibilities: (1) full-length talin M319A has higher affinity to integrin than
talin-H alone, thus leading to the more potent integrin activation. In addition to talin-H,
isolated talin-R also binds to integrin  CT (Xing et al., 2001; Yan et al., 2001; Tremuth
et al., 2004) at the membrane-distal region (Tremuth et al., 2004), but not the membrane-
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Figure 2.14. Talin autoinhibition and its effect on integrin activation. (A) Surface
representation of talin-PTB domain with the integrin 3 CT binding site highlighted. The
integrin binding site was based on Garcia-Alvarez et al., 2003 and Wegener et al., 2007.
The integrin membrane-proximal 3 CT binding residues are colored in green and the
membrane-distal 3 CT binding residues are colored in red. (B) The same view as (A)
but with the talin-RM binding site highlighted. Residues whose mutations impaired the
talin-RM binding are colored in green whereas other potential binding residues are
colored in cyan based on their significant chemical shift perturbation in Figure 3.6 and
competition data in Figure 3.10.-3.13.Notice the significant overlap of the integrin3
membrane-proximal binding site in green as compared to that for talin-RM in (B) also in
green.
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Figure 2.15. Comparison of the activity of integrin IIb3 by full-length talin, full length
talin M319A, and talin-H activation. Note that M319A is more potent than talin-H
probably due to its higher affinity for integrin 3 CT than talin-H due to synergistic talinH/integrin (unmasked) and talin-R/integrin interactions. **P<0.01; *P<0.05.
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proximal site (E.G. and J.Q., unpublished data). Thus, the constitutively open
conformation of M319A may have higher affinity for integrin than talin-H alone due to
both talin-H (M319A)/integrin and talin-R/integrin interactions. (2) Membrane anchoring
of talin is important for integrin activation (Vinogradova et al., 2004; Wegener et al.,
2007). It is possible that the open conformation of M319A has stronger capacity to
anchor to the membrane than talin-H, resulting in more potent integrin activation.

Conformational activation by PIP2
Given the above findings that talin-R interacts with talin-PTB and restrains talin in a
closed conformation, an obvious question is how this closed conformation is opened. A
well-known talin activator is phosphatidylinositol 4,5-bisphosphate (PIP2), which has
been shown to promote strong talin binding to integrin  CT (Martel et al., 2001),
resulting in the formation of a ternary PIP2/talin/integrin complex in living cells for
mediating integrin activation and clustering (Cluzel et al., 2005). Our SPR experiment
revealed that talin-H, but not talin-RM, can potently bind to biotinylated PIP2 with high
affinity (KD~89.2±1.25nM, Figure 2.16.A). The biotinylated PIP2 was mounted on a
biotin senor chip, and such positioned PIP2 should mimic the PIP2 anchored to the
membrane. Since talin-H contains FERM domain and multiple FERM domains have been
shown to bind to PIP2 involving PTB/PH subdomains (Hamada et al., 2000; Bompard et
al., 2003; Cai et al., 2008), we wondered if talin-PTB is involved in binding to PIP2. Our
HSQC-based mapping experiment revealed that PIP2 can indeed interact with talin-PTB
in a site-specific manner with the most significant perturbation around 370-378 (Figure
2.16.B), which overlaps with that for talin-RM (Figure 2.16.D). Consistently, SPR
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experiment demonstrated that PIP2 can indeed disrupt the talin-RM/talin-PTB interaction
in a concentration-dependent manner (Figure 2.17.A). Such competition was further
confirmed by HSQC experiment where soluble C4-PIP2 was able to compete with talinRM for binding to talin-PTB (Figure 2.17.B). Since PIP2/talin-H interaction has been
shown not to interfere with the talin-H/integrin interaction (see Figure 6 in Martel et al.,
2001) and instead it induces conformational change of talin for high affinity integrin
binding (Martel et al., 2001), our findings lead to a mechanism by which PIP2 binds to
talin-PTB and sterically displaces the inhibitory talin-R to expose the integrin binding site
for the effective talin/integrin interaction.

64

Figure 2.16. The Interaction of PIP2 with Talin. (A) SPR data showing the PIP2/talin-H
interaction. KD was estimated to be (89.2±1.25)x10-9M. (B) Chemical shift perturbation
data showing that soluble C4-PIP2 specifically binds to talin-PTB. Note that the chemical
shift changes are small indicating that the affinity between soluble C4-PIP2 and talinPTB is weaker than longer carbon chain PIP2 bound to talin-H.
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Figure 2.16. (continued) The PIP2/talin interaction (D) Surface representation of talinPTB domain with potential PIP2 binding site highlighted based on the chemical shift
mapping of significantly perturbed residues (Green, most significantly shifted, Cyan, next
significantly shifted).
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Figure 2.17. PIP2 disrupts the inhibitory talin-PTB/talin-RM interaction. (A) SPR data
showing that C8-PIP2 (echelon Bioscience, Inc) suppresses the talin-PTB interaction with
talin-RM in a concentration dependent manner. Talin-RM was immobilized to the
activated surface. Talin-PTB mixed with increasing amount of PIP2 was each injected at
the flow rate of 20µl/min. (B). Overlay of HSQC spectra of

15

N-labeled talin-PTB

showing that soluble C4-PIP2 (soluble at high concentration in 150mM NaCl, 50mM
phosphate buffer, pH 7.0) recovers many signals of talin-PTB (red), which were
otherwise broadened/disappeared in the presence of talin-RM (black) (talin-PTB:talinRM:PIP2 = 0.2mM:0.4mM:2.0mM).
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DISCUSSION

A combination of NMR spectroscopy, mutagenesis, and biochemical experiments
has revealed how talin-FERM, via its PTB subdomain, interacts with talin-R to restrain
talin in an inactive/autoinhibited conformation. Autoinhibition is a widespread
phenomenon in controlling protein functions, which has been shown to occur in multiple
FERM-containing proteins (Pearson et al., 2000; Li et al., 2007; Lietha et al., 2007).
However, only the talin FERM domain can directly mediate integrin activation
(Tadokoro et al., 2003) by binding to the integrin membrane-proximal  CT and inducing
integrin cytoplasmic unclasping (Vinogradova et al., 2002; Wegener et al., 2007). The
masking of the integrin membrane-proximal  CT binding site in talin-FERM by talin-R
is quite unique as compared to other autoinhibitory FERM-containing proteins, which
utilize FERM domains to autoinhibit the functions of other parts of proteins (Pearson et
al., 2000; Li et al., 2007; Lietha et al., 2007). For example, focal adhesion kinase (FAK)
utilizes its N-terminal FERM F2 domain to mask the C-terminal kinase active site (Lietha
et al., 2007) whereas moesin uses its N-terminal FERM F2 and F3 subdomains to mask
its C-terminal actin binding site. Thus, we have unraveled a novel autoinhibition
mechanism for talin in which other parts of the molecule talin-R, control the function of
the FERM domain in integrin activation.

Our cell-based experiments provide direct functional evidence to support the
mechanism that the full-length talin was a poor activator of integrin IIb3, whereas
talin-H was substantially more potent (Figure 2.1.). These data are also consistent with
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the report of Han et al, (2006) showing that talin must be activated to display its integrin
activating activity. Furthermore, talin M319A mutation, which disrupts the talinPTB/talin-R interaction but not talin-PTB/integrin interaction, constitutively activated
integrin IIb3 (Figure 2.15.). These data provides strong functional evidence for the talin
autoinhibition in regulating integrin activation. The autoinhibitory domain was mapped to
the middle region (1654-2344) of talin-R and its affinity for talin-PTB was found to be
within the submicromolar range as assessed by SPR using purified components (Table
2.1). We note that the intramolecular interaction involving the two domains in the intact
talin is expected to be even stronger by placing the binding surfaces within close
proximity within the same molecule, and may provide the tight control of the talin
activity needed to prevent, spontaneous integrin activation. Interestingly, despite its
inhibitory conformation that prevents the talin-PTB/integrin membrane-proximal  CT
contact, full-length talin can still bind weakly to integrin  CT (the affinity is about sixfold weaker than that of the talin-H/integrin interaction, see Yan et al., 2001), suggesting
that the integrin binding site on talin is not completely masked. Our data are consistent
with this observation in that the integrin membrane-distal CT binding site on talin-PTB
does not appear to be significantly masked by talin-R. Isolated talin-R was also shown to
bind to integrin  CT (Xing et al., 2001; Yan et al., 2001; Tremuth et al., 2004) at the
membrane-distal (Tremuth et al., 2004) but not the membrane-proximal side (Goksoy and
Qin, data not shown), which may contribute to the full length talin/integrin interaction.

Based on our observations, we propose a model for how talin controls integrin
activation via a closed (autoinhibitory) form to trigger conformational change (Figure
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2.18.). In the closed state, the integrin membrane-proximal  CT binding site on talin-H
is masked by talin-R, although talin can still weakly associate with integrin  CT via its
unmasked sites. Upon activation by cellular stimuli, talin undergoes conformational
change so that talin-PTB can access the integrin membrane-proximal  CT, which leads
to the integrin / CT unclasping and inside-out activation. Since talin also binds to actin
via the C-terminal end of talin-R (outside talin-RM) (Gingras et al., 2008), the enhanced
talin/integrin interaction, consequence to the talin conformational change, may alter the
strength of the integrin-actin linkage. In this manner, cells can undergo dynamic
cytoskeleton remodeling, movement or shape change in coordination with integrin
activation and ligation.

A dynamic equilibrium exists between monomeric and dimeric talin, which only
shifts to the dimeric state at high talin concentration (>3M) (Molony et al., 1987), and
the dimeric state may strengthen the integrin-actin linkage for regulating cell adhesion
and migration. Although the exact dimerization topology for the full length talin is not
clear, recent crystallographic studies of the C-terminal actin binding module (2300-2541)
revealed a dimer structure and have suggested that the full length talin dimer may exist in
three possible conformations (Gingras et al., 2008): parallel, tail-to-tail V-shaped or tailto-tail antiparallel fashion. Earlier EM studies (Goldman et al., 1994) suggested that the
two globular heads (talin-Hs) are on two opposite ends of the talin dimer and suggested a
head-to-tail antiparallel dimer, which raises a possibility that the middle talin-RM in one
subunit interacts with talin-H in the other. However, such head-to-tail antiparallel is
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incompatible with the crystallographic studies (Gingras et al., 2008) and thus the
intermolecular autoinhibition model is less likely to occur in cells.

What is the mechanism to trigger the conformational change of talin to expose its
integrin membrane-proximal  CT site in vivo? As illustrated above, one mechanism
appears to involve PIP2 which has been shown to promote strong talin binding to the
integrin  CT (Martel et al., 2001). Interestingly, the PIP2-producing enzyme, PIPKI,
has been shown to be recruited to the integrin adhesion sites by talin (Ling et al., 2002; di
Paolo et al., 2002), providing a mechanism for efficient PIP2/talin interaction. Our NMR
and biochemical data have indicated that while the PIPKI binding to talin does not affect
the autoinhibitory conformation of talin (Figure 2.10.D, i.e., PIPKI peptide did not
interfere with the talin-R/talin-PTB interaction), the PIPKI product, PIP2, does disrupt
the inhibitory talin-R/talin-PTB interaction (Figure 2.17.). Thus, upon agonist
stimulation, talin may recruit PIPKI to locally enrich PIP2, which in turn induces the
conformational change of talin to expose its integrin membrane-proximal  CT site,
promoting the high affinity talin binding to and activation of integrins. This model is
supported by several independent in vivo observations: (i) integrin αIIbβ3 activation was
found to be directly associated with the increased PIPKI activity and PIP2 levels in
platelets (Hinchliffe et al., 1996). (ii) PIP2 level is associated with talin on activated
platelets (which requires αIIbβ3 activation) but not on resting state platelets (Heraud et
al., 1998); and (iii) a ternary complex involving PIP2, talin, and integrin v3 was
formed in the living cells to mediate the integrin v3 activation and clustering (Cluzel
et al., 2005).
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Another emerging mechanism for the talin activation involves RIAM (Han et al.,
2006). Using a genetic approach, it was shown that RIAM may form a supramolecular
complex with talin and Rap1 to activate integrins. It remains to be determined whether
RIAM changes the conformation of talin in this supermolecular complex, leading to its
enhanced interaction with and activation of integrins. Finally, calpain has been shown to
cleave talin into a talin-H/talin-R mixture, thereby releasing talin-H for leading to
enhanced binding to integrin (Yan et al., 2001). However, activation of integrin αLβ2 by
ionomycin was found not to involve calpain-mediated talin cleavage (Dreolini and Takei,
2007). RIAM-mediated integrin activation also does not involve calpain-dependent talin
cleavage (Han et al., 2006). Most data implicate that calpain is involved in integrin
outside-in signaling (Schoenwaelder et al., 1997; Hayashi et al., 1999; Franco et al.,
2004).

In summary, we have demonstrated the structural basis of the autoinhibition for
talin in regulating integrin activation. Our findings, together with previous structural data
(Vinogradova et al., 2002; Garcia-Alvarez et al., 2003; Wegener et al., 2007), now
provide a view of how a series of conformational changes occur on the intracellular face
for talin-mediated integrin activation (Figure 2.18.).
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Figure 2.18. The model for the talin activation in inducing the integrin activation. In the
closed state, the integrin membrane-proximal  CT binding site (blue bar) on talin-H is
masked by talin-R, although talin can still weakly bind to integrin  CT via unmasked
sites. Upon activation by some cellular factor such as PIP2 or RIAM, talin undergoes
conformational change so that talin-PTB can access to the integrin membrane-proximal 
CT and induces the integrin / CT unclasping and integrin activation. Note the ternary
complex involving PIP2/talin/integrin has been indicated by Martel et al., 2001 and
Cluzel et al., 2005.
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CHAPTER III
TOWARDS STRUCTURE DETERMINATION OF TALIN-ROD4/ TALIN-PTB
COMPLEX

INTRODUCTION
Talin has long been known as a crucial regulator of a variety of cellular processes
such as cell spreading, migration, and proliferation. Its importance has been investigated
by many in vivo, in vitro and structural studies in recent years. On checking the Pubmed
for “talin”, nearly 1100 papers have been appeared that directly or indirectly related to
talin research. This promising field has been enriched by recent studies that revealed an
additional and very important role for talin. Talin binds to integrin  cytoplasmic tails,
and induces integrin activation by changing the integrin conformation for high affinity
ligand binding. In this major step, talin F3, or PTB domain of talin-H is the dominant
player in inducing integrin activation. In our recent paper, we used structural,
biochemical and mutational analyses to investigate the molecular details of talin
autoinhibition mechanism for

the regulation of integrin activation. By performing

NMR-based structural analyses, we showed that a middle segment of talin rod domain
(talin-RM) specifically interacts with talin-PTB domain for an autoinhibited
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conformation. We further demonstrated that talin-RM specifically binds a region in talinPTB where integrin  membrane proximal CT binds and competes with talin-RM for
binding to talin-PTB. Several studies show that this overlapping binding site on talinPTB is the key region for controlling the cytoplasmic unclasping and activation of
integrins.

Our studies have revealed that talin-RM fragment on talin rod domain is required for
talin head-rod interaction and autoinhibition of talin. To precisely minimize the binding
site of talin-RM from 70 kDa to 20-22kDa, we subcloned smaller fragments of this
construct and purified the labeled proteins and used for HSQC experiment to observe the
binding of talin-PTB to these smaller fragments. The chemical shift mapping revealed
that R4 (1654-1848) showed a very similar perturbation profile as talin-RM despite the
slightly reduced chemical shift changes (Figure 2.7). SPR experiment also confirmed the
binding by showing lower affinity (~3.6 M) than talin-RM (0.58M) (Table 2.1).
Moreover, we did a NMR-based competition experiment to understand whether this
binding is competed by 3 CT, and as shown in figure 2.13, 3 CT chimera replaced
talin-R4 from talin-PTB, indicating that R4 is the major binding site for talin-PTB and
this region is enough to mask the integrin binding site on talin-PTB.

To understand the structural details of the interaction of talin-R4 with talin-PTB at
atomic level, the talin-R4 structure has to be solved by NMR. Solving the 3-D structures
of proteins consists of many steps; some of them have to be repeated many times to
acquire an accurate structure. The first step is the preparation of labeled pure sample (13C,
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15

N labeled talin-R4 protein) for triple resonance experiments. The second step is the data

acquisition by NMR which takes 10-15 days to be completed. The following steps
include processing the data, the assignment of backbone and side chain resonances, the
generation of NOE restraints and structure calculations. Each of these steps may take
time from 1 week to few months to be completed, which totally depends on the quality of
NMR spectra (well-dispersed peaks vs overlapped peaks) and the size of protein (90
amino acid vs 200 amino acid).

In this chapter, the ongoing study of structure determination of talin-R4, and
especially published talin-R4 structure (by Critchley group) and the differences in the
results will be discussed in details.

METHODS AND MATERIALS

Sample Preparation for NMR experiments: Talin R4 (1654-1848) is subcloned
in pET-30a vector containing Factor-Xa cleavable N-terminal His tag. To prepare
13

15

N,

C-labeled talin-R4 protein, the cells were expressed in E. coli BL21(DE3) and grown in

M9 minimal media containing

15

NH4Cl and

13

C-glucose at 37 oC for 3 hrs with 1mM

IPTG. The cells were harvested by centrifugation and resuspended in 100 ml lysis buffer
(50mM NaPO4, 300mM NaCl, %0.001 detergent) containing 10mg/ml lysozyme, and
shaked at 4 oC for overnight. The double-labeled talin R4 protein was purified on nickel
column using elution buffer (50mM NaPO4 pH 8.0, 300mM NaCl, and 250mM
imidazole). The protein was then cut by Factor Xa to remove 5 kDa His-tag. The buffer is
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exchanged into a lower salt content buffer (50 mM NaPO4, 150mM NaCl, 1mM DTT, pH
7.0) and further purified by gel filtration using this buffer. The pure fractions of the
protein was collected and concentrated for NMR experiment. The protein concentration
was measured by Nano-drop, and 0.9mM talin-R4 protein was used for triple resonance
experiments.

For intermolecular NOE experiments, 15N-labeled talin-R4 and 15N-labeled talin-F3
proteins were grown in %100 D2O containing M9 minimal media. The proteins were
purified in the same way as previous proteins.

ELISA Assay: 96 well Maxisorp F96 Immunoplates (NalgeNunc) were coated with
1M wild type Talin-F3 in 100 l of 50mM carbonate buffer (pH 9.6) overnight at 40C
and blocked with 3% BSA in 1XPBS. Selected wells were incubated with either Talin-R4
alone or Talin-R4 preincubated with various amounts of wild type Talin-F3 or F3M319A
mutant or ovalbumin as a control. Because Talin-R4 bears S-Tag, the binding was
detected by HRP-conjugated anti-S-tag antibody (Pierce) and TMB substrate (Sigma).
The reaction was stopped by sulfuric acid and absorbance was measured by a 96-well
spectrophotometer at 450 nm.

Surface Plasmon Resonance Experiments: CM5 sensor chips were activated
using the amine coupling kit from Amersham Pharmacia Biotech. Talin-R4 was then
immobilized to the activated surface. Talin-PTB and its mutant were each injected at the
concentration range 0.1- 5μM and the flow rate was 20µl/min. The surfaces of the sensor
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chips were regenerated by injection of 20mM NaOH. Experiments were performed at
25oC in 10mM Hepes buffer, pH 7.4 on a BIA Core 3000 Instrument (Amersham
Pharmacia Biotech). All binding affinities were calculated using the BIAcore 3000
evaluation software (Biacore AB, Uppsala, Sweden).

RESULTS

3D NMR Structure of Talin-R4 Protein
It is well-known that talin is the final activator of integrins upon agonist
stimulation, and in the absence of signaling; integrins have a bent conformation in
inactive state. However, little was known about talin conformation in the resting state.
Using structural, and biochemical analyses, we showed that full length talin has an
autoinhibited conformation in the inactive state by binding of talin-PTB to a middle
fragment of talin rod. We were able to minimize the binding site from 70kDa to 20 kDa
using NMR experiments. To elucidate the structural details of talin-R4/talin-PTB
interaction, double-labeled talin-R4 protein was purified and used for NMR triple
resonance experiments for solving its 3D structure.

During the backbone assignment of Talin-R4, Critchley group from UK published
the NMR structure of talin R4 (1654-1822) on J. Biol. Chem. (Goult et al, 2009). Their
both talin-R4 structure and HADDOCK modeling studies confirm our published results
except one of the talin-PTB mutants. As on Figure 3.3, talin-R4 consists of five
antiparallel amphipathic -helices forming a bundle which is stabilized by hydrophobic

84

interactions. The topology of the bundle is similar to previously solved talin 482-655
fragment (Papagrigorio et al., 2004) and two bundles of talin 1974-2293, which contains
integrin binding site-2 (Gingras et al., 2009).

Structural Analysis of the Complex between Talin R4 and Talin-PTB
The interaction between the talin-R4 (1654-1848) and talin-PTB was studied by
collecting 1H,

15

N HSQC spectra of

15

N-labeled talin 1655–1822 in the presence of

unlabeled F3 at 1:0, 1:0.5, 1:1 and 1:2 ratios. The chemical shift perturbation map (Figure
3.1) shows that mostly helix 4 and helix 1 are involved in binding to talin-PTB which is
similar to those observed by Goult et al (Figure 3.3). They also show that this domain
binds to talin-PTB predominantly via surface-exposed residues on helix 4. They also
report the binding affinity of talin-R4/talin-PTB interaction as 20 M using NMR which
is similar to our SPR binding affinity (3.6M).

Both their chemical shift perturbation map (Figure 3.1) and competition experiment
and HADDOCK modeling of the complex confirm our hypothesis that talin-R4 rod
domain binds and masks the known binding site in talin-PTB for the 3-integrin
membrane proximal CT site whereas the 3-integrin membrane-distal CT site on talinPTB is not masked by talin-R.

Biochemical Studies of the Complex between Talin R4 and Talin-PTB
We previously examined the activity of talin M319A mutant in integrin activation
and found that this mutant still maintains the integrin binding, but has dramatically
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reduced the talin-PTB/talin-RM affinity (~140 fold). To evaluate the effect of talin-PTB
M319A mutation for binding to talin-R4, we did two SPR experiments. On the first
experiment, binding analysis showed that talin-R4 binds to Talin-PTB M319A with a
lower affinity (42M) (Table 2.1). On the second SPR experiment (data not shown), we
immobilized talin-R4 protein on chip, and flowed through both WT talin-PTB and
M319A mutant proteins. This spectrum confirms the SPR binding affinity that there is a
remarkable binding difference between WT and M319A talin-PTB. In addition to NMR
and BiaCore data, ELISA assay also shows that M319 of talin-PTB is a critical residue
for the interaction of talin-PTB with talin-R4. Talin F3 M319A mutant protein couldn’t
compete with coated WT F3 for binding to talin-R4 (Figure 3.1.). Although our results
confirm that there is a dramatic difference in binding of wild-type and mutant talin-PTB
to talin-R4, Goult et al. did not observe any difference in affinity from NMR Kd
measurements, interestingly their M319A talin-PTB mutant binds with a higher affinity
(14 M).

To partially map the binding sites and to check whether amide proton of M319 of
talin F3 involves in direct interaction with talin-R4 residues, we purified %100 D2O
grown,

15

N-labeled and unlabeled WT talin-F3 and R4 proteins for intermolecular NOE

experiment. The intermolecular NOEs were recorded by collecting two spectra, one of
15

N-labeled talin R4 in complex with the unlabeled talin F3 domain, and another of 15N-

labeled F3 in complex with unlabeled talin-R4. However, we couldn’t acquire a
significant result from this experiment.
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Amount of Competitor per 1 M R4

Figure 3.1. M319 is a critical residue for the interaction of talin-PTB with talin-R4.
ELISA assay showing that talin F3 M319A mutant protein couldn’t compete with coated
WT F3 for binding to talin-R4 in a concentration dependent manner. 1 M wild type
Talin-F3 were coated in 100l of 50 mM carbonate buffer (pH 9.6) overnight at 40C and
blocked with 3% BSA in 1XPBS. Selected wells were incubated with either Talin-R4
alone or Talin-R4 preincubated with various amounts of wild type Talin-F3 or F3M319A
mutant or ovalbumin as a control. Since Talin-R4 bears S-Tag, the binding was detected
by HRP-conjugated anti-S-tag antibody (Pierce) and TMB substrate (Sigma).
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Figure 3.2. Chemical shift perturbation map of talin R4 (1655-1822) in the presence of
talin F3
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Figure 3.3: Mapping the F3 FERM subdomain binding site in talin 1655–1822. C,
weighted shift map obtained from the 1H,

15

N HSQC spectra of talin 1655–1822 on the

addition of F3. D and E, residues in talin 1655–1822 that are significantly perturbed
following the addition of F3 are highlighted on the talin 1655–1822 structure. The most
significant shifts (0.2 ppm) are shown in dark blue, and the residue numbers are labeled;
smaller perturbations (0.07 ppm) are shown in light blue. F, residues in talin F3 (PDB
2H7D) that are significantly perturbed following the addition of talin 1655–1822 are
highlighted on the F3 structure. This figure and legend is adapted from Goult et al, 2009.
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DISCUSSION

Our previous NMR spectroscopy, mutagenesis, and biochemical experiments have
revealed how talin-FERM, via its PTB subdomain, interacts with talin-RM (1654-2344) to
restrain talin in an inactive/autoinhibited conformation. Within these region, we found
two PTB binding site, one of which (R4:1654-1848) has a higher affinity for talin-PTB
(Kd 3.6 M) than the other fragment (R6/8: 1984-2344, Kd 78 M). The affinity
difference between large talin RM (0.6M) and its smaller constructs suggests that
although the main binding site spans talin-R4 region, additional lower affinity
interactions with other domains in the vicinity may occur, and these interactions might
increase the overall affinity of the head-rod interaction.

We have started to determine the solution structure of talin-R4 followed by its
complex with talin-PTB. However, Goult et al. solved and published the NMR structure
of talin-R4 (1655-1822) before us. According to their HADDOCK modeling of the
complex, the talin-PTB binding site comprises two main interaction areas on talin-R4.
Tyr-377 of talin-F3 docks into a small hydrophobic pocket at the top of the helical
bundle. The second binding site (residues 316-326 of F3), also called F3 activation loop,
have many basic residues, and binds to a cluster of negatively charged residues on helix 4
of talin-R4. Our chemical shift perturbation map (Figure 3.2) also shows that helix 4 is
the main binding site of talin-PTB which is in agreement with their NMR results.
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Using NMR and biochemical analyses, we proposed a model (Figure 2.18) for how
talin controls integrin activation. In the closed state, the integrin membrane-proximal 
CT binding site but not membrane-distal  CT binding site on talin-H is masked by talinR. Importantly, PIPKI90 binding site in talin-PTB is exposed even in the autoinhibited
form of talin (Figure 2.10.D).Upon activation by cellular stimuli, PIPKI90, which is
activated by talin, then translocates the complex to the plasma membrane where PIP2
synthesis is locally enriched. PIP2 then induces the conformational change of talin to
expose its integrin membrane-proximal  CT, which leads to the integrin / CT
unclasping and inside-out activation. Our proposed model is similar to those observed by
Goult et al.

Although our results and conclusions are confirmed by the structure and model of
the talin-R4/PTB complex (Goult et al. 2009), one of their results is not in agreement
with our published and unpublished results. They claimed that M319 of talin-PTB is not
involved in direct binding to talin-R4 and interestingly, M319A talin-PTB mutant binds
talin-R4 with a higher affinity (14 M). The calculation of dissociation constant from
NMR titration experiment may not be highly reliable because of few reasons. During
NMR titration, one labeled protein is diluted with small increments of the binding partner
on each time, and during this process some of the sample is lost, which may affect the Kd
measurement, especially for weak interactions. Secondly, Kd calculation is totally
depends on the shift difference between bound and unbound ligand and especially big
proteins (≥ 15 kDa) have crowded and overlapped peaks on NMR spectra which makes
difficult to analyze their chemical shift values unambiguously. Finally, the common
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concept in the scientific field is to repeat the same experiment with different in vivo (if
applicable) and in vitro techniques to confirm the result. Using NMR chemical shift
mapping, BiaCore, ELISA, and integrin activation assay techniques, we confirm that
M319 of talin-PTB is critical for the inhibitory interaction of talin head-rod, and M319A
mutation disrupts this interaction leading to constitutively activated integrins.

In conclusion, the studies of talin-R4/talin-PTB interaction validate the structural
basis of autoinhibition, and provide a foundation for further structural studies.
Importantly, the 3D-complex structure of talin-R4/talin-PTB solved by NMR or X-ray
crystallography instead of modeling will show the structural details of the complex, and
this may correct the inconsistent results.
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CHAPTER IV
GENERAL DISCUSSION AND FUTURE WORK

The integrin have been studied over the fifty years at cellular, molecular and atomic
level to better understand cellular responses such as cell adhesion, migration, and
survival. Until this date, more than 150 components and more than 650 connections have
been described in integrin signaling. (Zaidel-Bar et al. 2007) However, more clinical and
basic research studies are required to appreciate the biological importance of each
component in integrin signaling.

In this thesis, we showed the molecular and structural details of talin regulation
using different NMR spectroscopy techniques. Although talin is too big (270 kDa) to
study with NMR, we successfully dissected talin into more than ten fragments without
disrupting their structural integrity. To study whether there is a head/rod interaction in
talin, we used fast and effective NMR method, HSQC to examine the protein-protein
interactions. Importantly, using deuterated talin fragments and TROSY method, we were
able to get well-resolved NMR spectra of large protein complexes and that enabled us to
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map the binding interfaces unambiguously. Also, we successfully used NMR as a tool for
different competition experiments, and for the detection of binding defective mutants.

We have unraveled a distinct autoinhibition mechanism for talin and a possible
release mechanism of its inhibited conformation by PIP2 using structural, biochemical,
mutational and cell-based techniques. Although a ternary PIP2/talin/integrin complex in
living cells has been reported, the mechanism how talin translocates to the membrane for
such a ternary complex has not been established yet. We showed that even in the
autoinhibited form of talin, PIPK binding site on talin is not masked by the
intramolecular interaction, and PIPK, which is activated by talin, is recruited to the
membrane, where PIP2 is locally synthesized. Locally enriched PIP2 then relieves
autoinhibited conformation of talin by competition, and exposes the integrin binding site
on talin-H.

Another mechanism for talin regulation has been defined recently in which
talin/Rap1A/RIAM complex binds to and activates the integrin. According to this
mechanism, activated GTP bound Rap1 translocates to the plasma membrane, where it
interacts with RIAM leading to the recruitment of talin for integrin activation (Han et al,
2006). Two important questions need to be answered. Han et al. showed that
talin/Rap1A/RIAM complex does not require calpain-cleavage or phosphorylation of
talin for integrin activation. Then, how talin is released from its autoinhibited
conformation? Does RIAM can lead a conformational change in talin to expose its
integrin binding site? Also, talin activity is tightly regulated by both PIPK/PIP2 and
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Rap1/RIAM but it is not known in which manner they work. Do they work
synergistically, simultaneously or mutually exclusive?

For years, talin was regarded as the only and final activator of the integrin;
however, recent studies have indicated that the kindlin family proteins (kindlin-1,-2, and 3) cooperate with talin for the regulation of integrin conformational shift from low to
high-affinity state (Ma et al, 2006; Moser et al, 2008). Biochemical studies showed that
kindlins also interact with integrins, but unlike talin, they bind only to the membranedistal region of integrin  cytoplasmic tails (Ma et al, 2008; Montanez et al, 2008);
therefore kindlins cannot activate integrins without talin, and talin itself is not sufficient
to induce integrin affinity. Although all these studies have opened a venue in the integrin
field, more questions remain to be answered. The binding modes of kindlin and talin
during integrin activation have to be investigated since their binding sites on integrins
partially overlap. Kindlins also have lipid binding sites like talin; therefore their activity
may also be regulated by phosphoinositide signals. It may worth to investigate lipidmediated kindlin regulation and its effects on talin and integrin activation. In general,
more functional and biochemical studies are required to understand the kindlin activity
and its signaling mechanism.

In conclusion, the structural studies of talin-mediated integrin activation make
significant contribution to the scientific field by answering the question of how talin
activity is regulated for efficient integrin activation. The researches will continue in
advance to answer more questions.
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APPENDIX A

Table A1: F2F3 chemical shift assignment table is electronically deposited in the
Biological Magnetic Resonance Data Bank with accession number 15792.
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APPENDIX B
Table B1. Chemical shift assignment values of talin R4 (1655-1822) free and talin
R4/talin F3 complex.

R4-free

R4+F3-1:2

no

aa no.

1H

15N

1H

15N

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
I665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692

8
0
8.72
7.81
8.638
9.83
8.21
8.24
8.558
8.08
8.41
7.65
7.96
8.53
8.63
7.82
7.95
8.46
7.72
7.87
8.55
8.69
8.25
8.07
8.46
7.97
7.86
8.77
8.35
7.39
7.97
8.47
8.01
8.34
0
7.97
8.48
0

128.14
0
111.56
120.35
121.491
121.29
117.02
119.3
117.058
126.18
119.86
121.82
122.28
122.03
118.52
116.79
120.67
119.68
120.09
121.51
122.67
122.65
118.79
122.66
114.95
122.17
122.54
122.22
119.21
113.62
116.15
115.39
124.74
132.75
0
124.97
117.07
0

8
0
8.75
7.81
8.638
9.84
8.21
8.24
8.558
8.09
8.45
7.62
7.95
8.51
8.59
7.84
7.96
8.48
7.67
7.84
8.42
8.59
8.25
8.05
8.35
7.97
7.85
8.76
8.34
7.45
7.86
8.53
7.97
8.33
0
7.94
8.48
0

128.12
0
111.8
120.27
121.491
121.31
117.15
119.31
117.058
126.14
119.7
121.65
122.44
122.15
118.65
116.71
120.48
119.7
119.68
121.32
122.86
123.93
119.1
122.72
115.25
122.36
122.16
122.58
118.43
113.1
115.81
115.36
124.97
132.81
0
124.88
117.24
0

105

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88

1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742

7.38
8.31
9.02
8.91
7.96
7.81
8.64
8.3
8.29
8.31
8.47
8.38
7.42
8.49
8.24
7.73
8
8.46
7.62
7.67
7.26
8.91
0
8.08
8.46
8.9
7.89
8.31
7.6
7.28
8.96
8.83
8.77
7.71
7.72
8.84
7.92
7.91
8.46
7.99
8
7.95
8.31
7.28
7.29
7.56
8.892
0
7.46
8.13

118.49
121.02
121.77
118.46
123.55
120.25
119.61
116.31
123.13
118.37
119.6
114.38
122.22
116.54
119.21
118.37
119.83
113.18
116.41
118.1
121.05
117.1
0
120.99
122.8
112.48
124.98
119.37
113.54
117.25
121.69
128.79
111.86
119.54
121.3
104.59
120.13
116.57
117.17
115.29
121.08
117.27
117.31
115.51
115.09
117.85
122.462
0
117.66
116.35

106

7.33
8.28
9.02
8.92
7.97
7.77
8.61
8.32
8.31
8.28
8.52
8.41
7.4
8.47
8.24
7.72
7.98
8.45
7.59
7.68
7.25
8.9
0
8.07
8.46
8.89
7.89
8.35
7.58
7.28
8.94
8.82
8.77
7.71
7.72
8.84
7.9
7.91
8.47
7.99
8
7.96
8.33
7.28
7.26
7.57
8.892
0
7.44
8.12

118.43
121.19
121.7
118.41
123.53
120.49
119.62
116.41
123.26
118.35
119.76
114.38
122.3
116.66
119.22
118.37
119.88
113.2
116.53
118.07
121.12
116.99
0
121.02
122.66
112.45
124.99
119.25
113.42
117.29
121.6
128.71
111.89
119.58
121.26
104.53
120.13
116.64
117.24
115.21
121.12
117.23
117.29
115.46
115.09
117.79
122.462
0
117.72
116.39

89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138

1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792

8.15
8.06
8.77
8.19
8.02
9.78
9.09
8.45
7.03
7.43
8.48
7.67
0
0
7.22
8.33
7.87
7.97
7.73
7.41
9.2
8.81
7.89
8.64
8.72
7.72
8.5
9.25
8.54
8.48
8.11
7.59
8.13
8.68
8.89
8.1
9.22
8.42
7.37
8.04
8.6
8.52
7.62
0
8.08
7.93
8.51
8.35
0
7.25

120.89
122.21
122.27
117.02
106.36
127.34
122.82
114.93
119.93
117.33
126.97
113.52
0
0
117.56
122.252
113.48
122.09
116.6
119.11
120.93
117.91
120.7
124.26
116.9
123.74
123.23
118.1
118.22
128.67
120.44
116.87
121.55
119.81
118.43
113.78
126.08
118.39
118.02
122.79
101.5
109.03
117.56
0
118.59
119.83
124.36
122.59
0
115.8

107

8.14
8.07
8.75
8.21
8.03
9.79
9.09
8.44
7.02
7.39
8.47
7.67
0
0
7.26
8.33
7.85
7.95
7.6
7.45
9.24
8.8
7.92
8.62
8.97
7.58
8.46
9.39
8.53
8.36
8.13
7.55
8.24
8.75
8.9
8.02
9.29
8.41
7.33
8.05
8.61
8.49
7.61
0
8.07
7.93
8.5
8.34
0
7.32

120.85
122.22
122.09
117.13
106.35
127.54
122.99
115.41
119.84
117.19
126.82
113.47
0
0
117.52
122.252
113.41
122.32
116.11
119.03
120.93
117.6
120.51
124.55
117.21
122.68
123.29
117.46
116.41
128.65
120.4
117.08
121.68
119.97
118.45
114.09
125.97
118.26
118.04
122.72
101.5
108.9
117.54
0
118.53
119.69
124.34
122.2
0
115.49

139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168

1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822

7.86
8.44
8.03
8.12
7.92
8.2
8.15
8.53
8.04
8.48
8.32
8.51
8.03
7.93
8.59
8.16
8.38
7.48
8.45
8.2
8.01
8.467
8.538
8.1
7.96
7.88
7.89
7.9
8.039
7.86

122.2
119.77
122.41
121.51
118.24
120.11
122.34
120.44
122.38
118.42
119.66
116.51
122.09
121.49
120.02
124.26
120.59
118.94
115.67
119.7
121.11
121.668
119.045
120.48
122.79
120.75
113.93
124.97
123.165
114.31

108

7.85
8.46
8.06
8.18
7.93
8.24
8.15
8.54
8.07
8.51
8.36
8.53
8.06
7.93
8.53
8.17
8.48
7.48
8.5
8.18
8.01
8.467
8.538
8.12
7.94
7.91
7.87
7.89
8.039
7.85

122.16
119.62
122.76
121.69
118.33
120.05
122.52
120.9
122.29
118.74
119.57
116.41
122.24
121.58
120.34
124.51
120.47
119.44
115.71
119.86
121.19
121.668
119.045
120.44
122.77
120.59
113.91
124.99
123.165
114.04

1
3

4
2
5

Figure B1. Backbone assignment of R4 (1654-1848). Numbered squares are zoomed on
the next pages.
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Figure B1. (continued) Zoomed squares are shown for better peak resolution.
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Figure B2. Chemical shift perturbation map of talin-F3 WT and M319A mutant upon
addition of talin-RM.
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